Human single nucleotide polymorphisms

Abstract

The invention provides nucleic acid segments of the human genome, particularly nucleic acid segments from genes including polymorphic sites. Allele-specific primers and probes hybridizing to regions flanking or containing these sites are also provided. The nucleic acids, primers and probes are used in applications such as phenotype correlations, forensics, paternity testing, medicine and genetic analysis.

Description

BACKGROUND OF THE INVENTION

[0002] The genomes of all organisms undergo spontaneous mutation in the course of their continuing evolution, generating variant forms of progenitor nucleic acid sequences (Gusella, Ann. Rev. Biochem. 55, 831-854 (1986)). The variant form may confer an evolutionary advantage or disadvantage relative to a progenitor form, or may be neutral. In some instances, a variant form confers a lethal disadvantage and is not transmitted to subsequent generations of the organism. In other instances, a variant form confers an evolutionary advantage to the species and is eventually incorporated into the DNA of many or most members of the species and effectively becomes the progenitor form. In many instances, both progenitor and variant form(s) survive and co-exist in a species population. The coexistence of multiple forms of a sequence gives rise to polymorphisms.

[0003] Several different types of polymorphism have been reported. A restriction fragment length polymorphism (RFLP) is a variation in DNA sequence that alters the length of a restriction fragment (Botstein et al., Am. J Hum. Genet. 32, 314-331 (1980)). The restriction fragment length polymorphism may create or delete a restriction site, thus changing the length of the restriction fragment. RFLPs have been widely used in human and animal genetic analyses (see WO 90/13668; WO90/11369; Donis-Keller, Cell 51, 319-337 (1987); Lander et al., Genetics 121, 85-99 (1989)). When a heritable trait can be linked to a particular RFLP, the presence of the RFLP in an individual can be used to predict the likelihood that the animal will also exhibit the trait.

[0004] Other polymorphisms take the form of short tandem repeats (STRs) that include tandem di-, tri- and tetra-nucleotide repeated motifs. These tandem repeats are also referred to as variable number tandem repeat (VNTR) polymorphisms. VNTRs have been used in identity and paternity analysis (US 5,075,217; Armour et al., FEBS Lett. 307, 113-115 (1992); Horn et al., WO 91/14003; Jeffreys, EP 370,719), and in a large number of genetic mapping studies.

[0005] Other polymorphisms take the form of single nucleotide variations between individuals of the same species. Such polymorphisms are far more frequent than RFLPs, STRs and VNTRs. Some single nucleotide polymorphisms (SNP) occur in protein-coding nucleic acid sequences (coding sequence SNP (cSNP)), in which case, one of the polymorphic forms may give rise to the expression of a defective or otherwise variant protein and, potentially, a genetic disease. Examples of genes in which polymorphisms within coding sequences give rise to genetic disease include β-globin (sickle cell anemia), apoE4 (Alzheimer's Disease), Factor V Leiden (thrombosis), and CFTR (cystic fibrosis). cSNPs can alter the codon sequence of the gene and therefore specify an alternative amino acid. Such changes are called “missense” when another amino acid is substituted, and “nonsense” when the alternative codon specifies a stop signal in protein translation. When the cSNP does not alter the amino acid specified the cSNP is called “silent”.

[0006] Other single nucleotide polymorphisms occur in noncoding regions. Some of these polymorphisms may also result in defective protein expression (e.g., as a result of defective splicing). Other single nucleotide polymorphisms have no phenotypic effects.

[0007] Single nucleotide polymorphisms can be used in the same manner as RFLPs and VNTRs, but offer several advantages. Single nucleotide polymorphisms occur with greater frequency and are spaced more uniformly throughout the genome than other forms of polymorphism. The greater frequency and uniformity of single nucleotide polymorphisms means that there is a greater probability that such a polymorphism will be found in close proximity to a genetic locus of interest than would be the case for other polymorphisms. The different forms of characterized single nucleotide polymorphisms are often easier to distinguish than other types of polymorphism (e.g., by use of assays employing allele-specific hybridization probes or primers).

[0008] Only a small percentage of the total repository of polymorphisms in humans and other organisms has been identified. The limited number of polymorphisms identified to date is due to the large amount of work required for their detection by conventional methods. For example, a conventional approach to identifying polymorphisms might be to sequence the same stretch of DNA in a population of individuals by dideoxy sequencing. In this type of approach, the amount of work increases in proportion to both the length of sequence and the number of individuals in a population and becomes impractical for large stretches of DNA or large numbers of persons.

SUMMARY OF THE INVENTION

[0009] Work described herein pertains to the identification of polymorphisms which can predispose individuals to disease, by resequencing large numbers of genes in a large number of individuals. Various genes from a number of individuals have been resequenced as described herein, and SNPs in these genes have been discovered (see the Table). Some of these SNPs are cSNPs which specify a different amino acid sequence (shown as mutation type “M” in the Table), some of the SNPs are silent cSNPs (shown as mutation type “S” in the Table), and some of these cSNPs specify a stop signal in protein translation (shown as an “N” in the “Mutation Type” column and an asterisk in the “Alt AA” column in the Table). Some of the identified SNPs were located in non-coding regions (indicated with a dash in the “Mutation Type” column in the Table).

[0010] The invention relates to a nucleic acid molecule which comprises a single nucleotide polymorphism at a specific location. In a particular embodiment the invention relates to the variant allele of a gene having a single nucleotide polymorphism, which variant allele differs from a reference allele by one nucleotide at the site(s) identified in the Table. Complements of these nucleic acid segments are also included. The segments can be DNA or RNA, and can be double- or single-stranded. Segments can be, for example, 5-10, 5-15, 10-20, 5-25, 10-30, 10-50 or 10-100 bases long.

[0011] The invention further provides allele-specific oligonucleotides that hybridize to a nucleic acid molecule comprising a single nucleotide polymorphism or to the complement of the nucleic acid molecule. These oligonucleotides can be probes or primers.

[0012] The invention further provides a method of analyzing a nucleic acid from an individual. The method allows the determination of whether the reference or variant base is present at any one of the polymorphic sites shown in the Table. Optionally, a set of bases occupying a set of the polymorphic sites shown in the Table is determined. This type of analysis can be performed on a number of individuals, who are also tested (previously, concurrently or subsequently) for the presence of a disease phenotype. The presence or absence of disease phenotype is then correlated with a base or set of bases present at the polymorphic site or sites in the individuals tested.

[0013] Thus, the invention further relates to a method of predicting the presence, absence, likelihood of the presence or absence, or severity of a particular phenotype or disorder associated with a particular genotype. The method comprises obtaining a nucleic acid sample from an individual and determining the identity of one or more bases (nucleotides) at specific (e.g., polymorphic) sites of nucleic acid molecules described herein, wherein the presence of a particular base at that site is correlated with a specified phenotype or disorder, thereby predicting the presence, absence, likelihood of the presence or absence, or severity of the phenotype or disorder in the individual.

[0014] The invention further relates to an oligonucleotide microarray having immobilized thereon a plurality of oligonucleotide probes specific for one or more nucleic acid molecules comprising a nucleic acid sequence selected from the group consisting of the nucleic acid sequences listed in the Table.

DETAILED DESCRIPTION OF THE INVENTION

[0015] The present invention relates to a nucleic acid molecule which comprises a single nucleotide polymorphism (SNP) at a specific location. The nucleic acid molecule, e.g., a gene, which includes the SNP has at least two alleles, referred to herein as the reference allele and the variant allele. The reference allele (prototypical or wild type allele) has been designated arbitrarily and typically corresponds to the nucleotide sequence of the nucleic acid molecule which has been deposited with GenBank or TIGR under a given Accession number. The variant allele differs from the reference allele by one nucleotide at the site(s) identified in the Table. The present invention also relates to variant alleles of the described genes and to complements of the variant alleles. The invention further relates to portions of the variant alleles and portions of complements of the variant alleles which comprise (encompass) the site of the SNP and are at least 5 nucleotides in length. Portions can be, for example, 5-10, 5-15, 10-20, 5-25, 10-30, 10-50 or 10-100 bases long. For example, a portion of a variant allele which is 21 nucleotides in length includes the single nucleotide polymorphism (the nucleotide which differs from the reference allele at that site) and twenty additional nucleotides which flank the site in the variant allele. These additional nucleotides can be on one or both sides of the polymorphism. Polymorphisms which are the subject of this invention are defined in the Table with respect to the reference sequence deposited in GenBank or TIGR under the Accession number indicated.

[0016] For example, the invention relates to a portion of a gene (e.g., dopamine receptor D1 (DRD1)) having a nucleotide sequence as deposited in GenBank or TIGR (e.g., under Accession No. M67439) comprising a single nucleotide polymorphism at a specific position (e.g., nucleotide 861). The reference nucleotide for this polymorphic form of DRD1 is shown in column 8 of the Table, and the variant nucleotide is shown in column 9 of the Table. In a preferred embodiment, the nucleic acid molecule of the invention comprises the variant (alternate) nucleotide at the polymorphic position. For example, the invention relates to a nucleic acid molecule which comprises the nucleic acid sequence shown in row 1, column 6, of the Table having a “G” at nucleotide position 704. The nucleotide sequences of the invention can be double- or single-stranded.

[0017] The invention further provides allele-specific oligonucleotides that hybridize to a gene comprising a single nucleotide polymorphism or to the complement of the gene. Such oligonucleotides will hybridize to one polymorphic form of the nucleic acid molecules described herein but not to the other polymorphic form(s) of the sequence. Thus, such oligonucleotides can be used to determine the presence or absence of particular alleles of the polymorphic sequences described herein. These oligonucleotides can be probes or primers.

[0018] The invention further provides a method of analyzing a nucleic acid from an individual. The method determines which base is present at any one of the polymorphic sites shown in the Table. Optionally, a set of bases occupying a set of the polymorphic sites shown in the Table is determined. This type of analysis can be performed on a number of individuals, who are also tested (previously, concurrently or subsequently) for the presence of a disease phenotype. The presence or absence of disease phenotype is then correlated with a base or set of bases present at the polymorphic site or sites in the individuals tested.

[0019] Thus, the invention further relates to a method of predicting the presence, absence, likelihood of the presence or absence, or severity of a particular phenotype or disorder associated with a particular genotype. The method comprises obtaining a nucleic acid sample from an individual and determining the identity of one or more bases (nucleotides) at polymorphic sites of nucleic acid molecules described herein, wherein the presence of a particular base is correlated with a specified phenotype or disorder, thereby predicting the presence, absence, likelihood of the presence or absence, or severity of the phenotype or disorder in the individual. The correlation between a particular polymorphic form of a gene and a phenotype can thus be used in methods of diagnosis of that phenotype, as well as in the development of treatments for the phenotype.

[0020] Definitions

[0021] An oligonucleotide can be DNA or RNA, and single- or double-stranded. Oligonucleotides can be naturally occurring or synthetic, but are typically prepared by synthetic means. Preferred oligonucleotides of the invention include segments of DNA, or their complements, which include any one of the polymorphic sites shown in the Table. The segments can be between 5 and 250 bases, and, in specific embodiments, are between 5-10, 5-20, 10-20, 10-50, 20-50 or 10-100 bases. For example, the segment can be 21 bases. The polymorphic site can occur within any position of the segment. The segments can be from any of the allelic forms of DNA shown in the Table.

[0022] As used herein, the terms “nucleotide”, “base” and “nucleic acid” are intended to be equivalent. The terms “nucleotide sequence”, “nucleic acid sequence”, “nucleic acid molecule” and “segment” are intended to be equivalent.

[0023] Hybridization probes are oligonucleotides which bind in a base-specific manner to a complementary strand of nucleic acid. Such probes include peptide nucleic acids, as described in Nielsen et al., Science 254, 1497-1500 (1991). Probes can be any length suitable for specific hybridization to the target nucleic acid sequence. The most appropriate length of the probe may vary depending upon the hybridization method in which it is being used; for example, particular lengths may be more appropriate for use in microfabricated arrays, while other lengths may be more suitable for use in classical hybridization methods. Such optimizations are known to the skilled artisan. Suitable probes and primers can range from about 5 nucleotides to about 30 nucleotides in length. For example, probes and primers can be 5, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 25, 26, 28 or 30 nucleotides in length. The probe or primer preferably overlaps at least one polymorphic site occupied by any of the possible variant nucleotides. The nucleotide sequence can correspond to the coding sequence of the allele or to the complement of the coding sequence of the allele.

[0024] As used herein, the term “primer” refers to a single-stranded oligonucleotide which acts as a point of initiation of template-directed DNA synthesis under appropriate conditions (e.g., in the presence of four different nucleoside triphosphates and an agent for polymerization, such as DNA or RNA polymerase or reverse transcriptase) in an appropriate buffer and at a suitable temperature. The appropriate length of a primer depends on the intended use of the primer, but typically ranges from 15 to 30 nucleotides. Short primer molecules generally require cooler temperatures to form sufficiently stable hybrid complexes with the template. A primer need not reflect the exact sequence of the template, but must be sufficiently complementary to hybridize with a template. The term primer site refers to the area of the target DNA to which a primer hybridizes. The term primer pair refers to a set of primers including a 5′ (upstream) primer that hybridizes with the 5′ end of the DNA sequence to be amplified and a 3′ (downstream) primer that hybridizes with the complement of the 3′ end of the sequence to be amplified.

[0025] As used herein, linkage describes the tendency of genes, alleles, loci or genetic markers to be inherited together as a result of their location on the same chromosome. It can be measured by percent recombination between the two genes, alleles, loci or genetic markers.

[0026] As used herein, polymorphism refers to the occurrence of two or more genetically determined alternative sequences or alleles in a population. A polymorphic marker or site is the locus at which divergence occurs. Preferred markers have at least two alleles, each occurring at frequency of greater than 1%, and more preferably greater than 10% or 20% of a selected population. A polymorphic locus may be as small as one base pair. Polymorphic markers include restriction fragment length polymorphisms, variable number of tandem repeats (VNTR's), hypervariable regions, minisatellites, dinucleotide repeats, trinucleotide repeats, tetranucleotide repeats, simple sequence repeats, and insertion elements such as Alu. The first identified allelic form is arbitrarily designated as the reference form and other allelic forms are designated as alternative or variant alleles. The allelic form occurring most frequently in a selected population is sometimes referred to as the wildtype form. Diploid organisms may be homozygous or heterozygous for allelic forms. A diallelic or biallelic polymorphism has two forms. A triallelic polymorphism has three forms.

[0027] Work described herein pertains to the resequencing of large numbers of genes in a large number of individuals to identify polymorphisms which can predispose individuals to disease. For example, polymorphisms in genes which are expressed in liver may predispose individuals to disorders of the liver.

[0028] By altering amino acid sequence, SNPs may alter the function of the encoded proteins. The discovery of the SNP facilitates biochemical analysis of the variants and the development of assays to characterize the variants and to screen for pharmaceutical that would interact directly with on or another form of the protein. SNPs (including silent SNPs) may also alter the regulation of the gene at the transcriptional or post-transcriptional level. SNPs (including silent SNPs) also enable the development of specific DNA, RNA, or protein-based diagnostics that detect the presence or absence of the polymorphism in particular conditions.

[0029] A single nucleotide polymorphism occurs at a polymorphic site occupied by a single nucleotide, which is the site of variation between allelic sequences. The site is usually preceded by and followed by highly conserved sequences of the allele (e.g., sequences that vary in less than {fraction (1/100)} or {fraction (1/1000)} members of the populations).

[0030] A single nucleotide polymorphism usually arises due to substitution of one nucleotide for another at the polymorphic site. A transition is the replacement of one purine by another purine or one pyrimidine by another pyrimidine. A transversion is the replacement of a purine by a pyrimidine or vice versa. Single nucleotide polymorphisms can also arise from a deletion of a nucleotide or an insertion of a nucleotide relative to a reference allele. Typically the polymorphic site is occupied by a base other than the reference base. For example, where the reference allele contains the base “T” at the polymorphic site, the altered allele can contain a “C”, “G” or “A” at the polymorphic site.

[0031] Hybridizations are usually performed under stringent conditions, for example, at a salt concentration of no more than 1 M and a temperature of at least 25° C. For example, conditions of 5× SSPE (750 mM NaCl, 50 mM NaPhosphate, 5 mM EDTA, pH 7.4) and a temperature of 25-30° C., or equivalent conditions, are suitable for allele-specific probe hybridizations. Equivalent conditions can be determined by varying one or more of the parameters given as an example, as known in the art, while maintaining a similar degree of identity or similarity between the target nucleotide sequence and the primer or probe used.

[0032] The term “isolated” is used herein to indicate that the material in question exists in a physical milieu distinct from that in which it occurs in nature. For example, an isolated nucleic acid of the invention may be substantially isolated with respect to the complex cellular milieu in which it naturally occurs. In some instances, the isolated material will form part of a composition (for example, a crude extract containing other substances), buffer system or reagent mix. In other circumstance, the material may be purified to essential homogeneity, for example as determined by PAGE or column chromatography such as HPLC. Preferably, an isolated nucleic acid comprises at least about 50, 80 or 90 percent (on a molar basis) of all macromolecular species present.

[0033] I. Novel Polymorphisms of the Invention

[0034] The novel polymorphisms of the invention are shown in the Table. Columns one and two show designations for the indicated polymorphism. Column three shows the Genbank or TIGR Accession number for the wild type (or reference) allele. Column four shows the location (nucleotide position) of the polymorphic site in the nucleic acid sequence with reference to the Genbank or TIGR sequence shown in column three. Column five shows common names for the gene in which the polymorphism is located. Column six shows the polymorphism and a portion of the 3′ and 5′ flanking sequence of the gene. Column seven shows the type of mutation; N, non-sense; S, silent; and M, missense. Columns eight and nine show the reference and alternate nucleotides, respectively, at the polymorphic site. Columns ten and eleven show the reference and alternate amino acids, respectively, encoded by the reference and variant, respectively, alleles.

[0035] II. Analysis of Polymorphisms

[0036] A. Preparation of Samples

[0037] Polymorphisms are detected in a target nucleic acid from an individual being analyzed. For assay of genomic DNA, virtually any biological sample (other than pure red blood cells) is suitable. For example, convenient tissue samples include whole blood, semen, saliva, tears, urine, fecal material, sweat, buccal, skin and hair. For assay of cDNA or mRNA, the tissue sample must be obtained from an organ in which the target nucleic acid is expressed. For example, if the target nucleic acid is a cytochrome P450, the liver is a suitable source.

[0038] Many of the methods described below require amplification of DNA from target samples. This can be accomplished by e.g., PCR. See generally PCR Technology: Principles and Applications for DNA Amplification (ed. H. A. Erlich, Freeman Press, NY, N.Y., 1992); PCR Protocols: A Guide to Methods and Applications (eds. Innis, et al., Academic Press, San Diego, Calif., 1990); Mattila et al., Nucleic Acids Res. 19, 4967 (1991); Eckert et al., PCR Methods and Applications 1, 17 (1991); PCR (eds. McPherson et al., IRL Press, Oxford); and U.S. Pat. No. 4,683,202.

[0039] Other suitable amplification methods include the ligase chain reaction (LCR) (see Wu and Wallace, Genomics 4, 560 (1989), Landegren et al., Science 241, 1077 (1988), transcription amplification (Kwoh et al., Proc. Natl. Acad. Sci. USA 86, 1173 (1989)), and self-sustained sequence replication (Guatelli et al., Proc. Nat. Acad. Sci. USA, 87, 1874 (1990)) and nucleic acid based sequence amplification (NASBA). The latter two amplification methods involve isothermal reactions based on isothermal transcription, which produce both single stranded RNA (ssRNA) and double stranded DNA (dsDNA) as the amplification products in a ratio of about 30 or 100 to 1, respectively.

[0040] B. Detection of Polymorphisms in Target DNA

[0041] There are two distinct types of analysis of target DNA for detecting polymorphisms. The first type of analysis, sometimes referred to as de novo characterization, is carried out to identify polymorphic sites not previously characterized (i.e., to identify new polymorphisms). This analysis compares target sequences in different individuals to identify points of variation, i.e., polymorphic sites. By analyzing groups of individuals representing the greatest ethnic diversity among humans and greatest breed and species variety in plants and animals, patterns characteristic of the most common alleles/haplotypes of the locus can be identified, and the frequencies of such alleles/haplotypes in the population can be determined. Additional allelic frequencies can be determined for subpopulations characterized by criteria such as geography, race, or gender. The de novo identification of polymorphisms of the invention is described in the Examples section.

[0042] The second type of analysis determines which form(s) of a characterized (known) polymorphism are present in individuals under test. There are a variety of suitable procedures, including, but not limited to, those discussed below.

[0043] 1. Allele-Specific Probes

[0044] The design and use of allele-specific probes for analyzing polymorphisms is described by e.g., Saiki et al., Nature 324, 163-166 (1986); Dattagupta, EP 235,726, Saiki, WO 89/11548. Allele-specific probes can be designed that hybridize to a segment of target DNA from one individual but do not hybridize to the corresponding segment from another individual due to the presence of different polymorphic forms in the respective segments from the two individuals. Hybridization conditions should be sufficiently stringent that there is a significant difference in hybridization intensity between alleles, and preferably an essentially binary response, whereby a probe hybridizes to only one of the alleles. Some probes are designed to hybridize to a segment of target DNA such that the polymorphic site aligns with a central position (e.g., in a 15-mer at the 7 position; in a 16-mer, at either the 8 or 9 position) of the probe. This design of probe achieves good discrimination in hybridization between different allelic forms.

[0045] Allele-specific probes are often used in pairs, one member of a pair showing a perfect match to a reference form of a target sequence and the other member showing a perfect match to a variant form. Several pairs of probes can then be immobilized on the same support for simultaneous analysis of multiple polymorphisms within the same target sequence.

[0046] 2. Tiling Arrays

[0047] The polymorphisms can also be identified by hybridization to nucleic acid arrays, some examples of which are described in WO 95/11995. The same arrays or different arrays can be used for analysis of characterized polymorphisms. WO 95/11995 also describes subarrays that are optimized for detection of a variant form of a precharacterized polymorphism. Such a subarray contains probes designed to be complementary to a second reference sequence, which is an allelic variant of the first reference sequence. The second group of probes is designed by the same principles as described, except that the probes exhibit complementarity to the second reference sequence. The inclusion of a second group (or further groups) can be particularly useful for analyzing short subsequences of the primary reference sequence in which multiple mutations are expected to occur within a short distance commensurate with the length of the probes (e.g., two or more mutations within 9 to 21 bases).

[0048] 3. Allele-Specific Primers

[0049] An allele-specific primer hybridizes to a site on target DNA overlapping a polymorphism and only primes amplification of an allelic form to which the primer exhibits perfect complementarity. See Gibbs, Nucleic Acid Res. 17, 2427-2448 (1989). This primer is used in conjunction with a second primer which hybridizes at a distal site. Amplification proceeds from the two primers, resulting in a detectable product which indicates the particular allelic form is present. A control is usually performed with a second pair of primers, one of which shows a single base mismatch at the polymorphic site and the other of which exhibits perfect complementarity to a distal site. The single-base mismatch prevents amplification and no detectable product is formed. The method works best when the mismatch is included in the 3′-most position of the oligonucleotide aligned with the polymorphism because this position is most destabilizing to elongation from the primer (see, e.g., WO 93/22456).

[0050] 4. Direct-Sequencing

[0051] The direct analysis of the sequence of polymorphisms of the present invention can be accomplished using either the dideoxy chain termination method or the Maxam—Gilbert method (see Sambrook et al., Molecular Cloning, A Laboratory Manual (2nd Ed., CSHP, New York 1989); Zyskind et al., Recombinant DNA Laboratory Manual, (Acad. Press, 1988)).

[0052] 5. Denaturing Gradient Gel Electrophoresis

[0053] Amplification products generated using the polymerase chain reaction can be analyzed by the use of denaturing gradient gel electrophoresis. Different alleles can be identified based on the different sequence-dependent melting properties and electrophoretic migration of DNA in solution. Erlich, ed., PCR Technology, Principles and Applicationsfor DNA Amplification, (W.H. Freeman and Co, New York, 1992), Chapter 7.

[0054] 6. Single-Strand Conformation Polymorphism Analysis

[0055] Alleles of target sequences can be differentiated using single-strand conformation polymorphism analysis, which identifies base differences by alteration in electrophoretic migration of single stranded PCR products, as described in Orita et al., Proc. Nat. Acad. Sci. 86, 2766-2770 (1989). Amplified PCR products can be generated as described above, and heated or otherwise denatured, to form single stranded amplification products. Single-stranded nucleic acids may refold or form secondary structures which are partially dependent on the base sequence. The different electrophoretic mobilities of single-stranded amplification products can be related to base-sequence differences between alleles of target sequences.

[0056] 7. Single Base Extension

[0057] An alternative method for identifying and analyzing polymorphisms is based on single-base extension (SBE) of a fluorescently-labeled primer coupled with fluorescence resonance energy transfer (FRET) between the label of the added base and the label of the primer. Typically, the method, such as that described by Chen et al., (PNAS 94:10756-61 (1997)), uses a locus-specific oligonucleotide primer labeled on the 5′ terminus with 5-carboxyfluorescein (FAM). This labeled primer is designed so that the 3′ end is immediately adjacent to the polymorphic site of interest. The labeled primer is hybridized to the locus, and single base extension of the labeled primer is performed with fluorescently-labeled dideoxyribonucleotides (ddNTPs) in dye-terminator sequencing fashion. An increase in fluorescence of the added ddNTP in response to excitation at the wavelength of the labeled primer is used to infer the identity of the added nucleotide.

[0058] III. Methods of Use

[0059] The determination of the polymorphic form(s) present in an individual at one or more polymorphic sites defined herein can be used in a number of methods.

[0060] A. Forensics

[0061] Determination of which polymorphic forms occupy a set of polymorphic sites in an individual identifies a set of polymorphic forms that distinguishes the individual. See generally National Research Council, The Evaluation of Forensic DNA Evidence (Eds. Pollard et al., National Academy Press, DC, 1996). The more sites that are analyzed, the lower the probability that the set of polymorphic forms in one individual is the same as that in an unrelated individual. Preferably, if multiple sites are analyzed, the sites are unlinked. Thus, polymorphisms of the invention are often used in conjunction with polymorphisms in distal genes. Preferred polymorphisms for use in forensics are biallelic because the population frequencies of two polymorphic forms can usually be determined with greater accuracy than those of multiple polymorphic forms at multi-allelic loci.

[0062] The capacity to identify a distinguishing or unique set of forensic markers in an individual is useful for forensic analysis. For example, one can determine whether a blood sample from a suspect matches a blood or other tissue sample from a crime scene by determining whether the set of polymorphic forms occupying selected polymorphic sites is the same in the suspect and the sample. If the set of polymorphic markers does not match between a suspect and a sample, it can be concluded (barring experimental error) that the suspect was not the source of the sample. If the set of markers does match, one can conclude that the DNA from the suspect is consistent with that found at the crime scene. If frequencies of the polymorphic forms at the loci tested have been determined (e.g., by analysis of a suitable population of individuals), one can perform a statistical analysis to determine the probability that a match of suspect and crime scene sample would occur by chance.

[0063] p(ID) is the probability that two random individuals have the same polymorphic or allelic form at a given polymorphic site. In biallelic loci, four genotypes are possible: AA, AB, BA, and BB. If alleles A and B occur in a haploid genome of the organism with frequencies x and y, the probability of each genotype in a diploid organism is (see WO 95/12607):

[0064] Homozygote: p(AA)=x2

[0065] Homozygote: p(BB)=y2=(1−x)2

[0066] Single Heterozygote: p(AB)=p(BA)=xy=x(1−x)

[0067] Both Heterozygotes: p(AB+BA)=2xy=2x(1−x)

[0068] The probability of identity at one locus (i.e, the probability that two individuals, picked at random from a population will have identical polymorphic forms at a given locus) is given by the equation:

p (ID)=(x2)2+(2xy)2+(y2)2.

[0069] These calculations can be extended for any number of polymorphic forms at a given locus. For example, the probability of identity p(ID) for a 3-allele system where the alleles have the frequencies in the population of x, y and z, respectively, is equal to the sum of the squares of the genotype frequencies:

p (ID)=x4+(2xy)2+(2yz)2+(2xz)2+z4+y4

[0070] In a locus of n alleles, the appropriate binomial expansion is used to calculate p(ID) and p(exc).

[0071] The cumulative probability of identity (cum p(ID)) for each of multiple unlinked loci is determined by multiplying the probabilities provided by each locus.

cum p (ID)=p(ID1)p(ID2)p(ID3) . . . p(IDn)

[0072] The cumulative probability of non-identity for n loci (i.e. the probability that two random individuals will be different at 1 or more loci) is given by the equation:

cum p (nonID)=1−cum p(ID).

[0073] If several polymorphic loci are tested, the cumulative probability of non-identity for random individuals becomes very high (e.g., one billion to one). Such probabilities can be taken into account together with other evidence in determining the guilt or innocence of the suspect.

[0074] B. Paternity Testing

[0075] The object of paternity testing is usually to determine whether a male is the father of a child. In most cases, the mother of the child is known and thus, the mother's contribution to the child's genotype can be traced. Paternity testing investigates whether the part of the child's genotype not attributable to the mother is consistent with that of the putative father. Paternity testing can be performed by analyzing sets of polymorphisms in the putative father and the child.

[0076] If the set of polymorphisms in the child attributable to the father does not match the set of polymorphisms of the putative father, it can be concluded, barring experimental error, that the putative father is not the real father. If the set of polymorphisms in the child attributable to the father does match the set of polymorphisms of the putative father, a statistical calculation can be performed to determine the probability of coincidental match.

[0077] The probability of parentage exclusion (representing the probability that a random male will have a polymorphic form at a given polymorphic site that makes him incompatible as the father) is given by the equation (see WO 95/12607):

p (exc)=xy(1−xy)

[0078] where x and y are the population frequencies of alleles A and B of a biallelic polymorphic site.

[0079] (At a triallelic site p(exc)=xy(1−xy)+yz(1−yz)+xz(1−xz)+3xyz(1−xyz))), where x, y and z and the respective population frequencies of alleles A, B and C).

[0080] The probability of non-exclusion is

p (non−exc)=1−p(exc)

[0081] The cumulative probability of non-exclusion (representing the value obtained when n loci are used) is thus:

cum p (non−exc)=p(non-exc1)p(non−exc2)p(non−exc3) . . . p(non−excn)

[0082] The cumulative probability of exclusion for n loci (representing the probability that a random male will be excluded)

cum p (exc)=1−cum p(non−exc).

[0083] If several polymorphic loci are included in the analysis, the cumulative probability of exclusion of a random male is very high. This probability can be taken into account in assessing the liability of a putative father whose polymorphic marker set matches the child's polymorphic marker set attributable to his/her father.

[0084] C. Correlation of Polymorphisms with Phenotypic Traits

[0085] The polymorphisms of the invention may contribute to the phenotype of an organism in different ways. Some polymorphisms occur within a protein coding sequence and contribute to phenotype by affecting protein structure. The effect may be neutral, beneficial or detrimental, or both beneficial and detrimental, depending on the circumstances. For example, a heterozygous sickle cell mutation confers resistance to malaria, but a homozygous sickle cell mutation is usually lethal. Other polymorphisms occur in noncoding regions but may exert phenotypic effects indirectly via influence on replication, transcription, and translation. A single polymorphism may affect more than one phenotypic trait. Likewise, a single phenotypic trait may be affected by polymorphisms in different genes. Further, some polymorphisms predispose an individual to a distinct mutation that is causally related to a certain phenotype.

[0086] Phenotypic traits include diseases that have known but hitherto unmapped genetic components (e.g., agammaglobulimenia, diabetes insipidus, Lesch-Nyhan syndrome, muscular dystrophy, Wiskott-Aldrich syndrome, Fabry's disease, familial hypercholesterolemia, polycystic kidney disease, hereditary spherocytosis, von Willebrand's disease, tuberous sclerosis, hereditary hemorrhagic telangiectasia, familial colonic polyposis, Ehlers-Danlos syndrome, osteogenesis imperfecta, and acute intermittent porphyria). Phenotypic traits also include symptoms of, or susceptibility to, multifactorial diseases of which a component is or may be genetic, such as autoimmune diseases, inflammation, cancer, diseases of the nervous system, and infection by pathogenic microorganisms. Some examples of autoimmune diseases include rheumatoid arthritis, multiple sclerosis, diabetes (insulin-dependent and non-independent), systemic lupus erythematosus and Graves disease. Some examples of cancers include cancers of the bladder, brain, breast, colon, esophagus, kidney, leukemia, liver, lung, oral cavity, ovary, pancreas, prostate, skin, stomach and uterus. Phenotypic traits also include characteristics such as longevity, appearance (e.g., baldness, obesity), strength, speed, endurance, fertility, and susceptibility or receptivity to particular drugs or therapeutic treatments.

[0087] The correlation of one or more polymorphisms with phenotypic traits can be facilitated by knowledge of the gene product of the wild type (reference) gene. The genes in which SNPs of the present invention have been identified are genes which have been previously sequenced and characterized in one of their allelic forms. Thus, the SNPs of the invention can be used to identify correlations between one or another allelic form of the gene with a disorder with which the gene is associated, thereby identifying causative or predictive allelic forms of the gene.

[0088] Correlation is performed for a population of individuals who have been tested for the presence or absence of a phenotypic trait of interest and for polymorphic markers sets. To perform such analysis, the presence or absence of a set of polymorphisms (i.e. a polymorphic set) is determined for a set of the individuals, some of whom exhibit a particular trait, and some of which exhibit lack of the trait. The alleles of each polymorphism of the set are then reviewed to determine whether the presence or absence of a particular allele is associated with the trait of interest. Correlation can be performed by standard statistical methods such as a κ-squared test and statistically significant correlations between polymorphic form(s) and phenotypic characteristics are noted. For example, it might be found that the presence of allele A1 at polymorphism A correlates with heart disease. As a further example, it might be found that the combined presence of allele A1 at polymorphism A and allele B1 at polymorphism B correlates with increased milk production of a farm animal.

[0089] Such correlations can be exploited in several ways. In the case of a strong correlation between a set of one or more polymorphic forms and a disease for which treatment is available, detection of the polymorphic form set in a human or animal patient may justify immediate administration of treatment, or at least the institution of regular monitoring of the patient. Detection of a polymorphic form correlated with serious disease in a couple contemplating a family may also be valuable to the couple in their reproductive decisions. For example, the female partner might elect to undergo in vitro fertilization to avoid the possibility of transmitting such a polymorphism from her husband to her offspring. In the case of a weaker, but still statistically significant correlation between a polymorphic set and human disease, immediate therapeutic intervention or monitoring may not be justified. Nevertheless, the patient can be motivated to begin simple life-style changes (e.g., diet, exercise) that can be accomplished at little cost to the patient but confer potential benefits in reducing the risk of conditions to which the patient may have increased susceptibility by virtue of variant alleles. Identification of a polymorphic set in a patient correlated with enhanced receptiveness to one of several treatment regimes for a disease indicates that this treatment regime should be followed.

[0090] For animals and plants, correlations between characteristics and phenotype are useful for breeding for desired characteristics. For example, Beitz et al., U.S. Pat. No. 5,292,639 discuss use of bovine mitochondrial polymorphisms in a breeding program to improve milk production in cows. To evaluate the effect of mtDNA D-loop sequence polymorphism on milk production, each cow was assigned a value of 1 if variant or 0 if wildtype with respect to a prototypical mitochondrial DNA sequence at each of 17 locations considered. Each production trait was analyzed individually with the following animal model:

Y ijkpn =μ+YS i +P j +X k +βi+ . . . β17+PEn+an+ep

[0091] where Yijknp is the milk, fat, fat percentage, SNF, SNF percentage, energy concentration, or lactation energy record; μ is an overall mean; YSi is the effect common to all cows calving in year-season; Xk is the effect common to cows in either the high or average selection line; β1 to β17 are the binomial regressions of production record on mtDNA D-loop sequence polymorphisms; PEn is permanent environmental effect common to all records of cow n; an is effect of animal n and is composed of the additive genetic contribution of sire and dam breeding values and a Mendelian sampling effect; and ep is a random residual. It was found that eleven of seventeen polymorphisms tested influenced at least one production trait. Bovines having the best polymorphic forms for milk production at these eleven loci are used as parents for breeding the next generation of the herd.

[0092] D. Genetic Mapping of Phenotypic Traits

[0093] The previous section concerns identifying correlations between phenotypic traits and polymorphisms that directly or indirectly contribute to those traits. The present section describes identification of a physical linkage between a genetic locus associated with a trait of interest and polymorphic markers that are not associated with the trait, but are in physical proximity with the genetic locus responsible for the trait and co-segregate with it. Such analysis is useful for mapping a genetic locus associated with a phenotypic trait to a chromosomal position, and thereby cloning gene(s) responsible for the trait. See Lander et al., Proc. Natl. Acad. Sci. (USA) 83, 7353-7357 (1986); Lander et al., Proc. Natl. Acad. Sci. (USA) 84, 2363-2367 (1987); Donis-Keller et al., Cell 51, 319-337 (1987); Lander et al., Genetics 121, 185-199 (1989)). Genes localized by linkage can be cloned by a process known as directional cloning. See Wainwright, Med. J. Australia 159, 170-174 (1993); Collins, Nature Genetics 1, 3-6 (1992).

[0094] Linkage studies are typically performed on members of a family. Available members of the family are characterized for the presence or absence of a phenotypic trait and for a set of polymorphic markers. The distribution of polymorphic markers in an informative meiosis is then analyzed to determine which polymorphic markers co-segregate with a phenotypic trait. See, e.g., Kerem et al., Science 245, 1073-1080 (1989); Monaco et al., Nature 316, 842 (1985); Yamoka et al., Neurology 40, 222-226 (1990); Rossiter et al., FASEB Journal 5, 21-27 (1991).

[0095] Linkage is analyzed by calculation of LOD (log of the odds) values. A lod value is the relative likelihood of obtaining observed segregation data for a marker and a genetic locus when the two are located at a recombination fraction θ, versus the situation in which the two are not linked, and thus segregating independently (Thompson & Thompson, Genetics in Medicine (5th ed, W.B. Saunders Company, Philadelphia, 1991); Strachan, “Mapping the human genome” in The Human Genome (BIOS Scientific Publishers Ltd, Oxford), Chapter 4). A series of likelihood ratios are calculated at various recombination fractions (θ), ranging from θ=0.0 (coincident loci) to θ=0.50 (unlinked). Thus, the likelihood at a given value of θ is: probability of data if loci linked at θ to probability of data if loci unlinked. The computed likelihoods are usually expressed as the log10 of this ratio (i.e., a lod score). For example, a lod score of 3 indicates 1000:1 odds against an apparent observed linkage being a coincidence. The use of logarithms allows data collected from different families to be combined by simple addition. Computer programs are available for the calculation of lod scores for differing values of θ (e.g., LIPED, MLINK (Lathrop, Proc. Nat. Acad. Sci. (USA) 81, 3443-3446 (1984)). For any particular lod score, a recombination fraction may be determined from mathematical tables. See Smith et al., Mathematical tables for research workers in human genetics (Churchill, London, 1961); Smith, Ann. Hum. Genet. 32, 127-150 (1968). The value of θ at which the lod score is the highest is considered to be the best estimate of the recombination fraction.

[0096] Positive lod score values suggest that the two loci are linked, whereas negative values suggest that linkage is less likely (at that value of θ) than the possibility that the two loci are unlinked. By convention, a combined lod score of +3 or greater (equivalent to greater than 1000:1 odds in favor of linkage) is considered definitive evidence that two loci are linked. Similarly, by convention, a negative lod score of −2 or less is taken as definitive evidence against linkage of the two loci being compared. Negative linkage data are useful in excluding a chromosome or a segment thereof from consideration. The search focuses on the remaining non-excluded chromosomal locations.

[0097] IV. Modified Polypeptides and Gene Sequences

[0098] The invention further provides variant forms of nucleic acids and corresponding proteins. The nucleic acids comprise one of the sequences described in the Table, column 5, in which the polymorphic position is occupied by one of the alternative bases for that position. Some nucleic acids encode full-length variant forms of proteins. Similarly, variant proteins have the prototypical amino acid sequences encoded by nucleic acid sequences shown in the Table, column 6, (read so as to be in-frame with the full-length coding sequence of which it is a component) except at an amino acid encoded by a codon including one of the polymorphic positions shown in the Table. That position is occupied by the variant or alternative amino acid shown in the Table.

[0099] Variant genes can be expressed in an expression vector in which a variant gene is operably linked to a native or other promoter. Usually, the promoter is a eukaryotic promoter for expression in a mammalian cell. The transcription regulation sequences typically include a heterologous promoter and optionally an enhancer which is recognized by the host. The selection of an appropriate promoter, for example trp, lac, phage promoters, glycolytic enzyme promoters and tRNA promoters, depends on the host selected. Commercially available expression vectors can be used. Vectors can include host-recognized replication systems, amplifiable genes, selectable markers, host sequences useful for insertion into the host genome, and the like.

[0100] The means of introducing the expression construct into a host cell varies depending upon the particular construction and the target host. Suitable means include fusion, conjugation, transfection, transduction, electroporation or injection, as described in Sambrook, supra. A wide variety of host cells can be employed for expression of the variant gene, both prokaryotic and eukaryotic. Suitable host cells include bacteria such as E. coli, yeast, filamentous fungi, insect cells, mammalian cells, typically immortalized, e.g., mouse, CHO, human and monkey cell lines and derivatives thereof. Preferred host cells are able to process the variant gene product to produce an appropriate mature polypeptide. Processing includes glycosylation, ubiquitination, disulfide bond formation, general post-translational modification, and the like. As used herein, “gene product” includes mRNA, peptide and protein products.

[0101] The protein may be isolated by conventional means of protein biochemistry and purification to obtain a substantially pure product, i.e., 80, 95 or 99% free of cell component contaminants, as described in Jacoby, Methods in Enzymology Volume 104, Academic Press, New York (1984); Scopes, Protein Purification, Principles and Practice, 2nd Edition, Springer-Verlag, New York (1987); and Deutscher (ed), Guide to Protein Purification, Methods in Enzymology, Vol. 182 (1990). If the protein is secreted, it can be isolated from the supernatant in which the host cell is grown. If not secreted, the protein can be isolated from a lysate of the host cells.

[0102] The invention further provides transgenic nonhuman animals capable of expressing an exogenous variant gene and/or having one or both alleles of an endogenous variant gene inactivated. Expression of an exogenous variant gene is usually achieved by operably linking the gene to a promoter and optionally an enhancer, and microinjecting the construct into a zygote. See Hogan et al., “Manipulating the Mouse Embryo, A Laboratory Manual,” Cold Spring Harbor Laboratory. Inactivation of endogenous variant genes can be achieved by forming a transgene in which a cloned variant gene is inactivated by insertion of a positive selection marker. See Capecchi, Science 244, 1288-1292 (1989). The transgene is then introduced into an embryonic stem cell, where it undergoes homologous recombination with an endogenous variant gene. Mice and other rodents are preferred animals. Such animals provide useful drug screening systems.

[0103] In addition to substantially fiull-length polypeptides expressed by variant genes, the present invention includes biologically active fragments of the polypeptides, or analogs thereof, including organic molecules which simulate the interactions of the peptides. Biologically active fragments include any portion of the full-length polypeptide which confers a biological function on the variant gene product, including ligand binding, and antibody binding. Ligand binding includes binding by nucleic acids, proteins or polypeptides, small biologically active molecules, or large cellular structures.

[0104] Polyclonal and/or monoclonal antibodies that specifically bind to variant gene products but not to corresponding prototypical gene products are also provided. Antibodies can be made by injecting mice or other animals with the variant gene product or synthetic peptide fragments thereof. Monoclonal antibodies are screened as are described, for example, in Harlow & Lane, Antibodies, A Laboratory Manual, Cold Spring Harbor Press, New York (1988); Goding, Monoclonal antibodies, Principles and Practice (2d ed.) Academic Press, New York (1986). Monoclonal antibodies are tested for specific immunoreactivity with a variant gene product and lack of immunoreactivity to the corresponding prototypical gene product. These antibodies are useful in diagnostic assays for detection of the variant form, or as an active ingredient in a pharmaceutical composition.

[0105] V. Kits

[0106] The invention further provides kits comprising at least one agent for identifying which alleleic form of the SNPs identified herein is present in a sample. For example, suitable kits can comprise at least one antibody specific for a particular protein or peptide encoded by one alleleic form of the gene, or allele-specific oligonucleotide as described herein. Often, the kits contain one or more pairs of allele-specific oligonucleotides hybridizing to different forms of a polymorphism. In some kits, the allele-specific oligonucleotides are provided immobilized to a substrate. For example, the same substrate can comprise allele-specific oligonucleotide probes for detecting at least 10, 100 or all of the polymorphisms shown in the Table. Optional additional components of the kit include, for example, restriction enzymes, reverse-transcriptase or polymerase, the substrate nucleoside triphosphates, means used to label (for example, an avidin-enzyme conjugate and enzyme substrate and chromogen if the label is biotin), and the appropriate buffers for reverse transcription, PCR, or hybridization reactions. Usually, the kit also contains instructions for carrying out the methods.

[0107] The following Examples are offered for the purpose of illustrating the present invention and are not to be construed to limit the scope of this invention. The teachings of all references cited herein are hereby incorporated herein by reference.

EXAMPLES

[0108] The polymorphisms shown in the Table were identified by resequencing of target sequences from individuals of diverse ethnic and geographic backgrounds by hybridization to probes immobilized to microfabricated arrays. The strategy and principles for design and use of such arrays are generally described in WO 95/11995. Accordingly, the invention encompasses an oligonucleotide microarray having immobilized thereon a plurality of oligonucleotide probes specific for one or more nucleic acid molecules comprising a nucleic acid sequence selected from the group consisting of the nucleic acid sequences listed in the Table.

[0109] A typical probe array used in this analysis has two groups of four sets of probes that respectively tile both strands of a reference sequence. A first probe set comprises a plurality of probes exhibiting perfect complementarily with one of the reference sequences. Each probe in the first probe set has an interrogation position that corresponds to a nucleotide in the reference sequence. That is, the interrogation position is aligned with the corresponding nucleotide in the reference sequence, when the probe and reference sequence are aligned to maximize complementarily between the two. For each probe in the first set, there are three corresponding probes from three additional probe sets. Thus, there are four probes corresponding to each nucleotide in the reference sequence. The probes from the three additional probe sets are identical to the corresponding probe from the first probe set except at the interrogation position, which occurs in the same position in each of the four corresponding probes from the four probe sets, and is occupied by a different nucleotide in the four probe sets. In the present analysis, probes were 25 nucleotides long. Arrays tiled for multiple different references sequences were included on the same substrate.

[0110] Publicly available sequences for a given gene were assembled into Gap4 (http://www.biozentrum.unibas.ch/˜biocomp/staden/Overview.html). PCR primers covering each exon were designed using Primer 3 (http://www-genome.wi.mit.edu/cgi-bin/primer/primer3.cgi). Primers were not designed in regions where there were sequence discrepancies between reads. Genomic DNA was amplified in at least 50 individuals using 2.5 pmol each primer, 1.5 mM MgCl2, 100 μM dNTPs, 0.75 μM AmpliTaq GOLD polymerase, and 19 ng DNA in a 15 μl reaction. Reactions were assembled using a PACKARD MultiPROBE robotic pipetting station and then put in MJ 96-well tetrad thermocyclers (96° C. for 10 minutes, followed by 35 cycles of 96° C. for 30 seconds, 59° C. for 2 minutes, and 72° C. for 2 minutes). A subset of the PCR assays for each individual were run on 3% NuSieve gels in 0.5X TBE to confirm that the reaction worked.

[0111] For a given DNA, 5 μl (about 50 ng) of each PCR or RT-PCR product were pooled (Final volume=150-200 μl). The products were purified using QiaQuick PCR purification from Qiagen. The samples were eluted once in 35 μl sterile water and 4 μl 10× One-Phor-All buffer (Pharmacia). The pooled samples were digested with 0.2μ DNaseI (Promega) for 10 minutes at 37° C. and then labeled with 0.5 nmols biotin-N6-ddATP and 15μ Terminal Transferase (GibcoBRL Life Technology) for 60 minutes at 37° C. Both fragmentation and labeling reactions were terminated by incubating the pooled sample for 15 minutes at 100° C.

[0112] Low-density DNA chips (Affymetrix, Calif.) were hybridized following the manufacturer's instructions. Briefly, the hybridization cocktail consisted of 3M TMACl, 10 mM Tris pH 7.8, 0.01% Triton X-100, 100 mg/ml herring sperm DNA (Gibco BRL), 200 pM control biotin-labeled oligo. The processed PCR products were denatured for 7 minutes at 100° C. and then added to prewarmed (37° C.) hybridization solution. The chips were hybridized overnight at 44° C. Chips were washed in 1× SSPET and 6× SSPET followed by staining with 2 μg/ml SARPE and 0.5 mg/ml acetylated BSA in 200 μl of 6× SSPET for 8 minutes at room temperature. Chips were scanned using a Molecular Dynamics scanner.

[0113] Chip image files were analyzed using Ulysses (Affymetrix, Calif.) which uses four algorithms to identify potential polymorphisms. Candidate polymorphisms were visually inspected and assigned a confidence value: high confidence candidates displayed all three genotypes, while likely candidates showed only two genotypes (homozygous for reference sequence and heterozygous for reference and variant). Some of the candidate polymorphisms were confirmed by ABI sequencing. Identified polymorphisms were compared to several databases to determine if they were novel. Results are shown in the Table.

		Genbank or TIGR	Position in			Mutation	Ref	Alt	Ref	Alt
Poly ID	WIAF ID	Accession Number	Sequence	Gene Description	Flanking Seq	Type	NT	NT	AA	AA
DRD5a64	WI-18269	M67439	861	DRD1, dopamine receptor D1	CTTCTACATCCCCGT[T/G]GCCATCATGATCGTG	S	T	G	V	V
DRD5a65	WI-18270	M67439	916	DRD1, dopamine receptor D1	GCCCAGGTGCAGATC[C/T]GCAGGATTTCCTCCC	M	C	T	R	C
DRD5a66	WI-18271	M67439	982	DRD1, dopamine receptor D1	AGCAGCGCAGCCTGC[G/A]CGCCCGACACCAGCC	M	G	A	A	T
G10a4	WI-18661	J04111	1366	JUN, v-jun avian sarcoma	CCCAAGATCCTGAAA[C/T]AGAGCATGACCCTGA	N	C	T	Q	*
				virus 17 oncogene homolog
G10a5	WI-18662	J04111	1595	JUN, v-jun avian sarcoma	AGGAGGGGTTCGCCG[A/G]GGGCTTCGTGCGCGC	M	A	G	E	G
				virus 17 oncogene homolog
G1041a4	WI-18958	X72886	451	H. sapiens TYRO3 mRNA., ?	GCAGAGGACATGACA[G/T]TGTGTGTGGCTGACT	M	G	T	V	L
G1092a1	WI-18960	HT0547	1703	KCNC4, potassium voltage-	AAGAGACTTCCCCCC[G/A]GGACAGCACCTGCAG	M	G	A	R	Q
				gated channel, Shaw-related
				subfamily, member 4
G1098a14	WI-19491	L19711	2723	DAG1, dystroglycan 1	ATGATCTGCTACCGC[A/C]AGAAGCGGAAGGGCA	M	A	C	K	Q
				(dystrophin-associated
				glycoprotein 1)
G1098a15	WI-19492	L19711	2758	DAG1,dystroglycan 1	TACCCTTGAGGACCA[G/A]GCCACCTTCATCAAG	S	G	A	Q	Q
				(dystrophin-associated
				glycoprotein 1)
G1124a1	WI-18959	HT0367	168	peripherin, ?	GAGCTCCTCGGTGCG[C/T]CTGGGCAGCTTCCGT	S	C	T	R	R
G1461a2	WI-18465	HT0329	1312	pRB-binding protein, ?	CGGGAGGACTTCTCC[G/A]GCCTCCTCCCTGAGG	M	G	A	G	S
G1461a3	WI-18466	HT0329	1514	pRB-binding protein, ?	AGCCCTGGAGCCCCC[T/C]GTCCCTGGCCGTCCT	-	T	C
G1461a4	WI-18799	HT0329	876	pRB-binding protein, ?	CCTGGCCTACGTGAC[G/A]TGTCAGGACCTTCGT	S	G	A	T	T
G1468a4	WI-18462	HT4968	1409	apoptosis inhibitor,	CGATCACACCAGATG[T/C]TTTCCCAATTGTCCA	S	T	C	C	C
				neuronal, ?
G1468a5	WI-18463	HT4986	1998	apoptosis inhibitor,	GTTACTGAAATGTGC[A/G]TGAGGAACATTATCC	M	A	G	M	V
				neuronal,
G1468a6	WI-18464	HT4986	2275	apoptosis inhibitor,	TGCGAAAGTTTATGG[T/G]TTACTTTGGAAAGAA	M	T	G	V	G
				neuronal, ?
G1479a11	WI-18964	Y09077	7570	ATR, ataxia telangiectasia	TGTAGATTTCAATTG[T/C]CTTTTCAATAAGGGA	S	T	C	C	C
				and Rad3 related
G1480a2	WI-18800	HT1406	841	G22P1, thyroid autoantigen	GTGATCTCTGTGGGC[A/G]TTTATAATCTGGTCC	M	A	G	I	V
				70kD (Ku antigen)
G1485a6	WI-18798	HT1432	3289	BCR, breakpoint cluster	AAAGCAAAGACGCGC[G/A]TCTACAGGGACACAG	M	G	A	V	I
				region
G1492a11	WI-18249	HT3506	558	cell death-associated	GGAGATCCAGCACCC[C/T]AATGTCATCACCCTG	S	C	T	P	P
				kinase, ?
G1500a1	WI-18467	HT2519	293	CSF2, colony stimulating	CCTGCGGGGCAGCCT[C/T]ACCAAGCTCAAGGGC	S	C	T	L	L
				factor 2 (granulocyte-
				macrophage)
G1500a2	WI-18468	HT2519	382	CSF2, colony stimulating	CCTGTGCAACCCAGA[T/C]TATCACCTTTGAAAG	M	T	C	I	T
				factor 2 (granulocyte-
				macrophage)
G1501a7	WI-18470	HT1949	494	MCC, mutated in colorectal	AGCGTCATTGCGGAG[C/T]TCAACAAGAAGATAG	M	C	T	L	F
				cancers
G1501a8	WI-18471	HT1949	1500	MCC, mutated in colorectal	AGGAATGTAAAAGCA[A/T]TGCTGAGAGGATGAG	M	A	T	N	I
				cancers
G1501a9	WI-18472	HT1949	2293	MCC, mutated in colorectal	CAGCGGCAGCAAAGA[T/C]AAACCTGGCAAGGAG	S	T	C	D	D
				cancers
G1502a3	WI-18251	HT1547	1006	CCND1 cyclin D1 (PRAD1:	GACCTGGCTTGCACA[C/T]CCACCGACGTGCGGG	M	C	T	P	S
				parathyroid adenomatosis 1)
G1515a3	WI-18250	HT2912	1137	CDH1, cadherin 1, E-	TGGTGGTTCAAGCTG[C/A]TGACCTTCAAGGTGA	M	C	A	A	D
				cadherin (epithelial)
G1517a13	WI-19556	HT1132	3389	ERBB3, v-erb-b2 avian	AGGGTAATCTTGGGG[G/A]GTCTTGCCAGGAGTC	M	G	A	G	E
				erythroblastic leukemia
				viral oncogene homolog 3
G1517a14	WI-19557	HT1132	3546	ERBB3, v-erb-b2 avian	AGTGTCAATGTGTAG[A/G]AGCCGGAGCAGGAGC	S	A	G	R	R
				erythroblastic leukemia
				viral oncogene homolog 3
G1517a15	WI-19558	HT1132	4280	ERBB3, v-erb-b2 avian	CAGCTAGTGCCTTTA[G/A]AGGGTACCGTCTTCT	-	G	A
				erythroblastic leukemia
				viral oncogene homolog 3
G1520a3	WI-18672	HT1175	730	DNA excision repair protein	CTGGACCCCAAGATT[G/A]CAGACCTGGTGTCCA	M	G	A	A	T
				ERCC2, 5′ end, ?
G1520a4	WI-19281	HT1175	1012	DNA excision repair protein	AACCCCGTGCTGCCC[G/A]ACGAAGTGCTGCAGG	M	G	A	D	N
				ERCC2, 5′ end, ?
G154a7	WI-19330	HT2645	2868	proto-oncogene c-kit, alt.	CAACCGACAGAAGCC[C/T]GTGGTAGACCATTCT	M	C	T		A
				transcript 1, ?
G1572a6	WI-18670	HT3998	2296	proto-oncogene c-abl,	GGAGCGCAGAGGGGC[C/T]GGCGAGGAAGAGGGC	S	C	T	A	A
				tyrosine protein kinase,
				alt. transcript 2, ?
G1572a7	WI-18673	HT3998	1117	proto-oncogene c-abl,	GGAGATGGAACGCAC[G/A]GACATCACCATGAAG	S	G	A	T	T
				tyrosine protein kinase,
				alt. transcript 2, ?
G1572a8	WI-18674	HT3998	2749	proto-oncogene c-abl,	AGTAACGCCTCCCCC[C/G]AGGCTGGTGAAAAAG	S	C	G	P	P
				tyrosine protein kinase,
				alt. transcript 2, ?
G1572a9	WI-18675	HT3998	2826	proto-oncogene c-abl,	GCCCGGGCTCCAGCC[C/T]GCCCAACCTGACTCC	M	C	T	P	L
				tyrosine protein kinase,
				alt. transcript 2, ?
G1572a10	WI-18676	HT3998	3859	proto-oncogene c-abl,	GGCTCGCCCATACCC[G/A]TGACAGTGGCTGACA	-	G	A
				tyrosine protein kinase,
				alt. transcript 2, ?
G1573a13	WI-18252	HT0642	300	CBL,Cas-Br-M (murine)	ACCCGCCGGGGACGG[T/C]GGACAAGAAGATGGT	M	T	C	V	A
				ecotropic retroviral
				transforming sequence
G1574a10	WI-18253	HT1508	1461	FES, feline sarcoma (Snyder-	GCAGCTGTGGTACCA[C/T]GGGGCCATCCCGAGG	S	C	T	H	H
				Theilen) viral (v-
				fes)/Fujinami avian sarcoma
				(PRCII) viral (v-fps)
				oncogene homolog
G1568a1	WI-18259	HT2291	465	SRC, v-src avian sarcoma	GTGGTATTTTGGCAA[G/A]ATCACCAGACGGGAG	S	G	A	K	K
				(Schmidt-Ruppin A-2) viral
				oncogene homolog
G1587a11	WI-18254	HT0590	1536	proto-oncogene dbl, ?	TTTTTCATCTAAACA[A/G]GGGAAGAAGACTTGG	S	A	G	Q	Q
G159a2	WI-18458	HT4209	1155	RAD23B, RAD23 (S.	TTGAATTTTTACGGA[A/T]TCAGCCTCAGTTTCA	M	A	T	N	I
				cerevisiae) homolog B
G159a3	WI-18659	HT4209	1415	RAD23B,RAD23 (S.	ACACCTCAGGAAAA[G/A]AAGCTATAGAAAGGT	M	G	A	E	K
				cerevisiae) homolog B
G159a4	WI-18660	HT4209	1474	RAD23B, RAD23 (S.	TGTGATACAAGCGTA[T/C]TTTGCTTGTGAGAAG	S	T	C	Y	Y
				cerevisiae) homolog B
G1602a2	WI-18260	HT1903	1426	proto-oncogene pim-1, ?	CCAGTGACACGTCTC[G/T]CCAAGCAGGACAGTG	-	G	T
G1602a3	WI-18261	HT1903	1427	proto-oncogene pim-1, ?	CAGTGACACGTCTCG[C/A]CAAGCAGGACAGTGC	-	C	A
G1602a4	WI-18262	HT1903	1346	proto-oncogene pim-1, ?	AGCAGCCTTTCTGGC[A/T]GGTCCTCCCCTCTCT	-	A	T
G1611a1	WI-18257	HT1316	1199	RB1, retinoblastoma 1	CAGTTTTGAAACACA[G/C]AGAACACCACGAAAA	M	G	C	Q	H
				(including osteosarcoma)
G1623a1	WI-18469	HT2205	350	TP53, tumor protein p53 (Li-	CAGAGGCTGCTCCCC[G/C]CGTGGCCCCTGCACC	M	G	C	R	P
				Fraumeni syndrome)
G1630a6	WI-18255	HT3563	951	DCC, deleted in colorectal	CACATATAAAAATGA[G/A]AATATTAGTGCCTCT	S	G	A	E	E
				carcinoma
G1630a7	WI-18256	HT3563	1995	DCC, deleted in colorectal	TCGACACAGAAAGAC[G/A]ACCCGCAGGGGTGAG	S	G	A	T	T
				carcinoma
G1632a4	WI-18666	HT27355	680	tumor suppressor, PDGF	TCGGCCAAAGTCACG[C/T]TCCACAGGGAATTCC	M	C	T	L	F
				receptor beta-like, ?
G1632a5	WI-18667	HT27355	853	tumor suppressor, PDGF	GTACCAGCTGCTCTA[C/T]GTGGCGGTTCCCAGT	S	C	T	Y	Y
				receptor beta-like, ?
G1633a8	WI-18663	HT1778	2619	FER, fer (fps/fes related)	GAGTGACGTGTGGAG[C/T]TTTGGCATCCTTCTC	S	C	T	S	S
				tyrosine kinase
				(phosphoprotein NCP94)
G1633a9	WI-18668	HT1778	2136	FER, fer (fps/fes related)	GGGCACATTAAAGGA[T/C]AAAACTTCTGTTGCT	S	T	C	D	D
				tyrosine kinase
				(phosphoprotein NCP94)
G1635a1	WI-19559	HT1472	1353	LCK, lymphocyte-specific	GCTGACGGAAATTGT[C/A]ACCCACGGCCGCATC	S	C	A	V	V
				protein tyrosine kinase
G1645a9	WI-18664	D21089	247	XPC, xeroderma pigmentosum,	CCAAAGAAGAGCCTT[C/T]TCTCCAAAGTTTCAC	M	C	T	L	F
				complementation group C
G1645a10	WI-18665	D21089	3024	XPC, xeroderma pigmentosum,	CCCTGGTGGTGGGGG[G/C]TTCTCTGCTGAGAAG	-	G	C
				complementation group C
G1645a11	WI-18669	D21089	1636	XPC, xeroderma pigmentosum,	AGCAGTAAAAGAGGC[A/C]AGAAAATGTGCAGCG	M	A	C	K	Q
				complementation group C
G167a13	WI-18655	HT4579	1890	PMS2L8, postmeiotic	CCTGGACTTTTCTAT[G/A]AGTTCTTTAGCTAAA	M	G	A	M	I
				segregation increased 2-like
				8
G185a13	WI-19560	X77533	183	ACVR2B, activin A receptor,	AGCGGCTGCACTGCT[A/G]CGCCTCCTGGGCCAA	M	A	G	Y	C
				type IIB
G185a14	WI-19561	X77533	272	ACVR2B, activin A receptor,	TACGATAGGCAGGAG[T/G]GTGTGGCCACTGAGG	M	T	G	C	G
				type IIB
G188a1	WI-18440	AB000221	234	SYCA3, small inducible	CCAGTGCCCCAAGCC[A/G]GGTGTCATCCTCCTA	S	A	G	P	P
				cytokine A3 (homologous to
				mouse Mip-1a)
G188a2	WI-18441	AB000221	289	SCYA3, small inducible	GCTGACCCCAATAAG[A/T]AGTGGGTCCAGAAAT	N	A	T	K	*
				cytokine A3 (homologous to
				mouse Mip-1a)
G192a1	WI-18481	D12614	292	LTA, lymphotoxin alpha (TNF	AGACTGCCCGTCAGC[A/C]CCCCAAGATGCATCT	M	A	C	H	P
				superfamily, member 1)
G192a2	WI-18482	D12614	319	LTA, lymphotoxin alpha (TNF	ATCTTGCCCACAGCA[C/A]CCTCAAACCTGCTGC	M	C	A	T	N
				superfamily, member 1)
G192a3	WI-18483	D12614	177	LTA, lymphotoxin alpha (TNF	TTCCTCCCAAGGGTG[T/C]GTGGCACCACCCTAC	M	T	C	C	R
				superfamily, member 1)
G197a3	WI-18206	D50403	1825	NRAMP1, natural resistance-	TGCAGGCAGCAGGAT[G/A]GAGTGGGACAGTTCC	-	G	A
				associated macrophage
				protein 1 (might include
				Leishmaniasis)
G197a4	WI-18962	D50403	737	NRAMP1, natural resistance-	TGAGTATGTGGTGGC[G/A]CGTCCTGAGCAGGGA	S	G	A	A	A
				associated macrophage
				protein 1 (might include
				Leishmaniasis)
G208a2	WI-18504	L31581	528	CCR7, chemokine (C-C motif)	CATCAGCATTGACCG[C/A]TACGTGGCCATCGTC	S	C	A	R	R
				receptor 7
G208a3	WI-18678	L31581	975	CCR7, chemokine (C-C motif)	TGAGCTCAGTAAGCA[A/G]CTCAACATCGCCTAC	S	A	G	Q	Q
				receptor 7
G212a1	WI-19161	M24854	624	FCGR3A, Fc fragment of IgG,	TTCTGCAGGGGGCTT[G/T]TTGGGAGTAAAAATG	M	G	T	V	F
				low affinity IIIa, receptor
				for (CD16)
G215a7	WI-18653	M28393	900	PRF1, perforin 1	CTACCGGGAGCGCCA[T/C]TCGGAAGTGGTTGGC	S	T	C	H	H
				(preforming protein)
G215a8	WI-19278	M28393	1330	PRF1, perforin 1	GTGAAGCTCTTCTTT[G/C]GTGGCCAGGAGCTGA	M	G	C	G	R
				(preforming protein)
G217a7	WI-18433	M31932	195	FCGR2B, Fc fragment of IgG,	TGACTCTGACATGCC[A/G]GGGGGCTCGCAGCCC	M	A	G	Q	R
				low affinity IIb, receptor
				for (CD32)
G217a8	WI-18434	M31932	507	FCGR2B, Fc fragment of IgG,	CCCAGAAATTCTCCC[G/A]TTTGGATCCCACCTT	M	G	A	R	H
				low affinity IIb, receptor
				for (CD32)
G217a9	WI-18446	M31932	652	FCGR2B, Fc fragment of IgG,	GGGCAGCTCTTCACC[A/G]ATGGGGATCATTGTG	S	A	G	P	P
				low affinity IIb, receptor
				for (CD32)
G217a10	WI-18447	M31932	904	FCGR2B, Fc fragment of IgG,	GGCACCTACTGACGA[T/C]GATAAAAACATCTAC	S	T	C	D	D
				low affinity IIb, receptor
				for (CD32)
G218a12	WI-18512	M36712	729	CD8B1, CD8 antigen, beta	GACATCGGTCAGTAA[T/C]GAGCACGATGTGGAA	-	T	C
				polypeptide 1 (p37)
G218a13	WI-18513	M36712	820	CD8B1, CD8 antigen, beta	TTTCACTGCTGCAAG[G/A]CCTTTCTGTGTGTGA	-	G	A
				polypeptide 1 (p37)
G218a14	WI-18681	M36712	221	CD8B1, CD8 antigen, beta	GGCTGAGACAGCGCC[A/T]GGCACCGAGCAGTGA	M	A	T	Q	L
				polypeptide 1 (p37)
G227a3	WI-18442	M86511	1090	CD14, CD14 antigen	CCTGGAACTGCCCTC[C/T]CCCACGAGGGCTCAA	M	C	T	P	S
G2273a2	WI-18171	AF004883	4979	CACNA1A, calcium channel,	GGCCATGATCGCCCT[C/A]AACACCATCGTGCTT	S	C	A	L	L
				voltage-dependent, P/Q type,
				alpha 1A subunit
G228a3	WI-18435	U00672	241	IL10RA, interleukin 10	CTGCTATGAAGTGGC[G/A]CTCCTGAGGTATGGA	S	G	A	A	A
				receptor, alpha
G228a4	WI-18436	U00672	1112	IL10RA, interleukin 10	AGAACGCTGGGAAAC[G/A]GGGAGCCCCCTGTGC	M	G	A	G	R
				receptor, alpha
G228a5	WI-18437	U00672	1320	IL10RA, interleukin 10	ACACACAGGGTGGCT[C/T]GGCCTTGGGCCACCA	M	C	T	S	L
				receptor, alpha
G228a6	WI-18438	U00672	1033	IL10RA, interleukin 10	TGGCTTTGGCAGCAC[C/T]AAGCCATCCCTGCAG	S	C	T	T	T
				receptor, alpha
G2288a5	WI-18532	D29634	701	PTGIR, prostaglandin 12	CCCTCAGCCTCTGCC[G/A]CATGTACCGCCAGCA	M	G	A	R	H
				(prostacyclin) receptor (IP)
G2295a5	WI-18475	D89079	1524	LTB4R, leukotriene b4	GAAGAAGAGGGAGAG[A/G]TGGAGCAAAGTGAGG	-	A	G
				receptor (chemokine receptor-
				like 1)
G230a2	WI-18448	U31628	892	IL15RA, interleukin 15	CCACCTATGAAACTC[G/A]GGGAAACCAGCCCAG	-	G	A
				receptor, alpha
G231a2	WI-19159	U32324	189	IL11RA, interleukin 11	GGCAGCCAGGGAGGT[C/T]CGTGAAGCTGTGTTG	M	C	T	S	F
				receptor, alpha
G2314a3	WI-18265	J05272	1999	IMPDH1, IMP (inosine	GCAGGCATCCAACAC[G/T]GCTGCCAGGATATCG	M	G	T	G	C
				monophosphate) dehydrogenase
				1
G2316a1	WI-18817	J05594	173	HPGD, hydroxyprostaglandin	TGCCCTGCATGAGCA[A/G]TTTGAACCTCAGAAG	S	A	G	Q	Q
				dehydrogenase 15-(NAD)
G2330a6	WI-18686	L22607	1007	ADORA3, adenosine A3	TGGCTGCCTTTATCT[A/C]TCATCAACTGCATCA	M	A	C	I	L
				receptor
G2330a7	WI-18687	L22607	1134	ADORA3, adenosine A3	AAATAAAGAAGTTCA[A/T]GGAAACCTACCTTTT	M	A	T	K	M
				receptor
G2335a9	WI-18266	L32961	492	ABAT, 4-aminobutyrate	AACAGACCCGCCCTC[G/A]AAATCCTGCCTCCGG	M	G	A	E	K
				aminotransferase
G2335a10	WI-18267	L32961	1114	ABAT, 4-aminobutyrate	GCACGGGCAAGTTCT[G/A]GGCCCATGAGCACTG	N	G	A	W	*
				aminotransferase
G2335a11	WI-18268	L32961	1245	ABAT, 4-aminobutyrate	ATCTTCAACACGTGG[C/T]TGGGGGACCCGTCCA	S	C	T	L	L
				aminotransferase
G2355a4	WI-18500	M16405	1963	CHRM4, cholinergic	AGGTGCGCAAGAAGC[G/A]GCAGATGGCGGCCCG	M	G	A	R	Q
				receptor, muscarinic 4
G236a4	WI-19162	U84487	628	SCYD1, small inducible	AGGGCCTGTGGGCAC[G/T]GAGCTTTTCCGAGTG	S	G	T	T	T
				cytokine subfamily D (Cys-X3-
				Cys), member 1 (fractalkine,
				neurotactin)
G236a5	WI-19163	U84487	728	SCYD1, small inducible	GAGGCAAAGACCTCT[G/A]AGGCCCCGTCCACCC	M	G	A	E	K
				cytokine subfamily D (Cys-X3-
				Cys), member 1 (fractalkine,
				neurotactin)
G2363a7	WI-19439	HT4822	673	CSF1, colony stimulating	TACAGGTGGAGGCGG[C/A]GGAGCCATCAAGAGC	M	C	A		R
				factor 1 (macrophage)
G2363a8	WI-19440	HT4822	698	CSF1, colony stimulating	AAGAGCCTCAGAGAG[C/T]GGATTCTCCCTTGGA	M	C	T		R
				factor 1 (macrophage)
G2373a2	WI-18812	M36035	546	BZRP, benzodiazapine	ACAACCATGGCTGGC[A/G]TGGGGGACGGCGGCT	M	A	G	H	R
				receptor (peripheral)
G2376a2	WI-18813	M57414	1124	TACR2, tachykinin receptor	GTGGGGAGGCGGGGC[G/A]TCCCCAGGATGGATC	M	G	A	R	H
				2
G2376a3	WI-18814	M57414	1128	TACR2, tachykinin receptor	GGAGGCGGGGCGTCC[C/T]CAGGATGGATCAGGG	S	C	T	P	P
				2
G240a2	WI-19160	X04391	1125	Human mRNA for lymphocyte	GCTGTCCCAGTGCCA[C/T]GAACTTTGGGAGAGA	S	C	T	H	H
				glycoprotein T1/Leu-1., ?
G2403a4	WI-18522	M83670	272	CA4, carbonic anhydrase IV	CTTCTTCTCTGGCTA[C/T]GATAAGAAGCAAACG	S	C	T	Y	Y
G2403a5	WI-18523	M83670	1003	CA4, carbonic anhydrase IV	GGCTCACTTCTGCAC[G/A]CAGCCTCTCTGTTGC	-	G	A
G2409a2	WI-19006	M93394	745	AGTR1, angiotensin receptor	CCAAAATTCAACCCT[T/C]CCGATAGGGCTGGGC	S	T	C	L	L
				1
G2425a1	WI-19567	U03865	294	ADRA1B, adrenergic, alpha-	GGGCGCCTTCATCCT[C/T]TTTGCCATCGTGGGC	S	C	T	L	L
				1B-, receptor
G2425a2	WI-19568	U03865	417	ADRA1B, adrenergic, alpha-	GTTGAGCTTCACCGT[C/T]CTGCCCTTCTCAGCG	S	C	T	V	V
				1B-, receptor
G2425a3	WI-19569	U03865	502	ADRA1B, adrenergic, alpha-	GCAGCCGTGGATGTC[C/T]TGTGCTGCACAGCGT	S	C	T	L	L
				1B-, receptor
G2425a4	WI-19570	U03865	672	ADRA1B, adrenergic, alpha-	CGGGCCTCTCCTTGG[G/A]TGGAAGGAGCCGGCA	S	G	A	G	G
				1B-, receptor
G2430a1	WI-19571	U09353	520	LCT4S, leukotriene C4	TGAGACCAAGGCCCC[C/T]GGGCCGACGGAGCCG	-	C	T
				synthase
G2452a1	WI-18235	U63970	3127	CMOAT, canalicular	AGTCTACGGAGCTCT[G/A]GGATTAGCCCAAGGT	S	G	A	L	L
				multispecific organic anion
				transporter
G2452a2	WI-18392	U63970	2583	CMOAT, canalicular	CCTACAGTGCTCTCC[T/G]GGCCAAAAAAGGAGA	M	T	G	L	R
				multispecific organic anion
				transporter
G2452a3	WI-18393	U63970	4327	CMOAT, canalicular	GTTATCCCACGAAGT[G/T]ACAGAGGCTGGTGGC	S	G	T	V	V
				multispecific organic anion
				transporter
G2482a1	WI-19167	X56088	1004	CYP7A1, cytochrome P450,	GAACATTAGAGAATG[C/T]TGGTCAAAAAGTCAG	M	C	T	A	V
				subfamily VIIA (chloesterol
				7 alpha-monooxygenase),
				polypeptide 1
G250a3	WI-19279	HT0155	521	IL3RA, interleukin 3	GAGCTGCAGCTGGGC[G/A]GTAGGCCCGGGGGCC	S	G	A	A	A
				receptor, alpha (low
				affinity)
G2513a19	WI-18372	HT27365	1242	PLCB3, phospholipase C,	CGAAGCGTTGAACTC[G/A]ATGTAAGTGATGGTT	M	G	A	D	N
				beta 3 (phosphatidylinositol-
				specific)
G2513a20	WI-18373	HT27365	1269	PLCB3, phospholipase C,	GGTTCAGATAATGAA[C/T]CAATCCTTTGTAATC	M	C	T	P	S
				beta 3 (phosphatidylinositol-
				specific)
G2513a21	WI-18374	HT27365	1616	PLCB3, phospholipase C,	GTCTCGAAGGATGTC[G/A]GTAGATTACAATGGT	S	G	A	S	S
				beta 3 (phosphatidylinositol-
				specific)
G2513a22	WI-18375	HT27365	2399	PLCB3, phospholipase C,	TGTTCCCCTGCGTTC[T/C]TTTGTGGGTGACATC	S	T	C	S	S
				beta 3, (phosphatidylinositol-
				specific)
G2513a23	WI-18376	HT27365	2430	PLCB3, phospholipase C,	ATGGAGCACGTAACC[C/T]TTTTTGTCCACATAG	M	C	T	L	F
				beta 3 (phosphatidylinositol-
				specific)
G2513a24	WI-18377	HT27365	2756	PLCB3, phospholipase C,	ACTTGTGATGAAAGA[C/T]AGCTTTCCTTACCTG	S	C	T	D	D
				beta 3 (phosphatidylinositol-
				specific)
G2513a25	WI-18378	HT27365	3006	PLCB3, phospholipase C,	GCTTGGAACATTACA[G/A]TATTGAAGGGCCAAG	M	G	A	V	I
				beta 3 (phosphatidylinositol-
				specific)
G2513a26	WI-18379	HT27365	3137	PLCB3, phospholipase C,	TGCTGAGGCCAAGAG[C/T]AAGCGCAGCCTGGAA	S	C	T	S	S
				beta 3 (phosphatidtlinositol-
				specific)
G2514a2	WI-19572	Z46632	1142	PDE4C, phosphodiesterase	ACGTAAGTGGGAACC[G/A]GCCCCTCACAGCTAT	M	G	A	R	Q
				4C, cAMP-specific (dunce
				(Drosophila)-homolog
				phosphodiesterase E1)
G2514a3	WI-19573	Z46632	1245	PDE4C, phosphodiesterase	CCTGCTGATGCTGGA[G/A]GGTCACTACCACGCC	S	G	A	E	E
				4C, cAMP-specific (dunce
				(Drosophila)-homolog
				phosphodiesterase E1)
G2514a4	WI-19574	Z46632	1259	PDE4C, phosphodiesterase	AGGGTCACTACCACG[C/T]CAATGTGGCCTACCA	M	C	T	A	V
				4C, cAMP-specific (dunce
				(Drosophila)-homolog
				phosphodiesterase E1)
G2514a5	WI-19575	Z46632	1269	PDE4C, phosphodiesterase	CCACGCCAATGTGGC[C/T]TACCACAACAGCCTA	S	C	T	A	A
				4C, cAMP-specific (dunce
				(Drosophila)-homolog
				phosphodiesterase E1)
G2514a6	WI-19576	Z46632	1332	PDE4C, phosphodiesterase	GCTGCTGGCTACGCC[C/T]GCCCTCGAGGCTGTG	S	C	T	P	P
				4C, cAMP-specific (dunce
				(Drosophila)-homolog
				phosphodiesterase E1)
G252a3	WI-18449	HT0425	912	FCER2, Fc fragment of IgE,	GAAGGGAGAGTTTAT[C/T]TGGGTGGATGGGAGC	S	C	T	I	I
				low affinity II, receptor
				for (CD23A)
G252a4	WI-18450	HT0425	1032	FCER2, Fc fragment of IgE,	GAACGACGCCTTCTG[C/T]GACCGTAAGCTGGGC	S	C	T	C	C
				low affinity II, receptor
				for (CD23A)
G253a2	WI-18484	HT0573	303	IFNB1, interferon, beta 1,	CCAGAAGGAGGACGC[C/T]GCATTGACCATCTAT	S	C	T	A	A
				fibroblast
G253a3	WI-18526	HT0573	537	IFNB1, interferon, beta 1,	GATTCTGCATTACCT[G/A]AAGGCCAAGGAGTAC	S	G	A	L	L
				fibroblast
G254a4	WI-18451	HT0611	987	IL4R, interleukin 4	TTCCCAACCCAGCCC[G/A]CAGCCGCCTCGTGGC	M	G	A	R	H
				receptor
G254a5	WI-18452	HT0611	1682	IL4R, interleukin 4	CGCAGCTTCAGCAAC[T/C]CCCTGAGCCAGTCAC	M	T	C	S	P
				receptor
G261a3	WI-18439	HT1101	349	IL7R, interleukin 7	GAGCAATATATGTGT[G/A]AAGGTTGGAGAAAAG	S	G	A	V	V
				receptor
G261a4	WI-18443	HT1101	1260	IL7R, interleukin 7	TTGGGACTACAAACA[G/A]CACGCTGCCCCCTCC	M	G	A	S	N
				receptor
G261a5	WI-18444	HT1101	1263	IL7R, interleukin 7	GGACTACAAACAGCA[C/T]GCTGCCCCCTCCATT	M	C	T	T	M
				receptor
G261a6	WI-18445	HT1101	1366	IL7R, interleukin 7	AAATCAAGAAGAAGC[A/T]TATGTCACCATGTCC	S	A	T	A	A
				receptor
G261a7	WI-18453	HT1101	753	IL7R, interleukin 7	ATCCTATCTTACTAA[C/T]CATCAGCATTTTGAG	M	C	T	T	I
				receptor
G261a8	WI-18454	HT1101	1088	IL7R, interleukin 7	TCTGAGGATGTAGTC[G/A]TCACTCCAGAAAGCT	M	G	A	V	I
				receptor
G2648a1	WI-18240	HT2947	946	HSD17B1, hydroxysteroid (17-	GACGAGGCCGGGCGC[A/G]GTGCGGTGGGGGACC	M	A	G	S	G
				beta) dehydrogenase 1
G2648a2	WI-18241	HT2947	1070	HSD17B1, hydroxysteroid (17-	CTGGGGATGGGGCGG[C/T]GGTAGCAGCTGTGGG	-	C	T
				beta) dehydrogenase 1
G266a2	WI-19349	M55646	458	IL1RN, interleukin 1	CATCCGCTCAGACAG[T/C]GGCCCCACCACCAGT	S	T	C	S	S
				receptor antagonist
G266a3	WI-19350	M55646	471	IL1RN, interleukin 1	AGTGGCCCCACCACC[A/G]GTTTTGAGTCTGCCG	M	A	G	S	G
				receptor antagonist
G266a4	WI-19351	M55646	239	IL1RN, interleukin 1	CAACCAACTAGTTGC[T/C]GGATACTTGCAAGGA	S	T	C	A	A
				receptor antagonist
G27a1	WI-18242	M73832	1004	CSF2RA, colony stimulating	CCCGCCAGTTCCACA[G/C]ATCAAAGACAAACTG	M	G	C		D
				factor 2 receptor, alpha,
				low-affinity (granulocyte-
				macrophage)
G27a2	WI-18243	M73832	1133	CSF2RA, colony stimulating	TACCTGAGACCCAGA[G/A]GGTGTAGGAATGGCA	-	G	A
				factor 2 receptor, alpha,
				low-affinity (granulocyte-
				macrophage)
G275a1	WI-18961	HT3654	1048	CD8A, CD8 antigen, alpha	ACGACGCCAGCGCCG[C/A]GACCACCAACACCGG	S	C	A	R	R
				polypeptide (p32)
G275a2	WI-19164	HT3654	810	CD8A, CD8 antigen, alpha	GCCGCGCGGCGCCGC[C/A]GCCAGTCCCACCTTC	S	C	A	A	A
				polypeptide (p32)
G275a3	WI-19165	HT3654	897	CD8A, CD8 antigen, alpha	GTTCTCGGGCAAGAG[G/A]TTGGGGGACACCTTC	S	G	A	R	R
				polypeptide (p32)
G276a4	WI-18505	HT3670	681	CD4 antigen, ?	CCAAGGGGTAAAAAC[A/C]TACAGGGGGGGAAGA	M	A	C	I	L
G276a5	WI-18506	HT3670	874	CD4 antigen, ?	CCTTCCCACTCGCCT[T/C]TACAGTTGAAAAGCT	M	T	C	F	S
G276a6	WI-18507	HT3670	893	CD4 antigen, ?	AGTTGAAAAGCTGAC[G/T]GGCAGTGGCGAGCTG	S	G	T	T	T
G276a7	WI-18508	HT3670	987	CD4 antigen, ?	GAAGTGTCTGTAAAA[C/T]GGGTTACCCAGGACC	M	C	T	R	W
G276a8	WI-18509	HT3670	1486	CD4 antigen, ?	GGCGCCAAGCAGAGC[G/A]GATGTCTCAGATCAA	M	G	A	R	Q
G276a9	WI-18510	HT3670	1645	CD4 antigen, ?	TGCCTGCGGACCAGA[T/A]GAATGTAGCAGATCC	-	T	A
G276a10	WI-18511	HT3670	1668	CD4 antigen, ?	GCAGATCCCCAGCCT[C/T]TGGCCTCCTGTTCGC	-	C	T
G276a11	WI-18679	HT3670	1079	CD4 antigen, ?	GTATGCTGGCTCTGG[A/G]AACCTCACCCTGGCC	S	A	G	G	G
G276a12	WI-18680	HT3670	1201	CD4 antigen, ?	GGGGACCCACCTCCC[C/T]TAAGCTGATGCTGAG	M	C	T	P	L
G279a21	WI-18791	K01740	1500	F8C, coagulation factor	CCGATTTATGGCATA[C/T]ACAGATGAAACCTTT	S	C	T	Y	Y
				VIIIc, procoagulant
				component (hemophilia A)
G281a5	WI-18797	L06105	701	FDFT1, farnesyl-diphosphate	AAACATCATCCGTGA[C/T]TATCTGGAAGACCAG	S	C	T	D	D
				farnesyltransferase 1
G2959a3	WI-18174	HT0134	1624	GRLF1, glucocorticoid	GCTCAAGAAATTGAC[G/A]GAAGGTTCACAAGCA	M	G	A	G	R
				receptor DNA binding factor
				1
G297a6	WI-18796	U16660	738	ECH1, enoyl Coenzyme A	GATGGCTGACGAGGC[C/T]CTGGACAGTGGGCTG	S	C	T	A	A
				hydratase 1, peroxisomal
G2982a2	WI-18533	HT0358	1802	homeotic protein 7, notch	GTCACAGTGGTCACC[T/A]CCAGGGTGAGCATCC	M	T	A	L	H
				group, ?
G2991a1	WI-18476	HT0534	221	ZFP36, zinc finger protein	GTCACCTCCCGCCTG[C/T]CTGGCCGCTCCACCA	M	C	T	P	S
				homologous to zfp-36 in
				mouse
G3012a3	WI-18264	HT0873	761	MAD, MAX dimerization	GCTATTCCAGCACCA[G/A]CATCAAGAGAATAAA	M	G	A	S	N
				protein
G3023a9	WI-18170	HT0966	366	zinc finger, X-linked,	GTTTTCCTGCTCTTT[C/T]CCTGGCTGCAGCAAG	S	C	T	F	F
				duplicated A, ?
G3029a4	WI-18536	HT1100	813	zinc finger protein 8, ?	CTCCCTCGTCCAGCA[T/C]GAGCGCATCCACACT	S	T	C	H	H
G3029a5	WI-18537	HT1100	1703	zinc finger protein 8, ?	ATAGTGTACTCATGG[A/G]AGGAGGGGCTGGGGG	-	A	G
G3034a3	WI-18496	HT1182	178	TCF12, transcription factor	AGCTTGGCTTTATCA[A/G]CCAGAGACCGAGGCT	M	A	G	T	A
				12 (HTF4, helix-loop-helix
				transcription factors 4)
G3050a8	WI-18806	HT1558	1748	?, ?	ATACCTACCACTGTC[C/T]TCAACATTCCCCACC	M	C	T	L	F
G3050a9	WI-18807	HT1558	2704	?, ?	AAAAGAGAAAAAGAA[G/T]AAACGGAAGGCAGAG	M	G	T	K	N
G3050a10	WI-18808	HT1558	3178	?, ?	GAAACCCCGGAAGCC[C/T]TACACCATTAAGAAG	S	C	T	P	P
G3057a23	WI-18688	HT1669	7874	alpha-fetoprotein enhancer-	AGATGGTGCTTCACG[T/C]CCCCACCGGCGGCGG	M	T	C	V	A
				binding protein, ?
G3114a2	WI-19564	HT2617	588	GTF2E2, general	CCAAAATTGAAGTAA[T/C]AGATGGGAAGTATGC	M	T	C	I	T
				transcription factor IIE,
				polypeptide 2 (beta subunit,
				34kD)
G3118a3	WI-18514	HT2652	1241	ZNF35, zinc finger protein	GCTCAAACCTCATTG[T/C]CCACCAGAGGATCCA	M	T	C	V	A
				35 (clone HF.10)
G3119a8	WI-18515	HT2654	2179	GLI, glioma-associated	GCTGCCATGGATGCT[A/G]GAGGGCTACAGGAAG	M	A	G	R	G
				oncogene homolog (zinc
				finger protein)
G3119a9	WI-18516	HT2654	2300	GLI, glioma-associated	AAGGGGCAGCAGCTG[A/G]GCCTTATGGAGCGAG	M	A	G	E	G
				oncogene homolog (zinc
				finger protein)
G3119a10	WI-18517	HT2654	3113	GLI, glioma-associated	CAAACCCCAGCTGTG[G/T]TCATCCTGAGGTGGG	M	G	T	G	V
				oncogene homolog (zinc
				finger protein)
G3122a1	WI-18518	HT2671	1177	HOXB2, homeo box B2	TCCCGGTCCTTTCGA[C/T]CCCCGCGCTCCTTGG	-	C	T
G3124a2	WI-18525	HT2673	607	HOXB3, homeo box B3	GGTCTGGCCCCCGAG[A/C]CCCTGTCGGCCCCGC	M	A	C	T	P
G3129a2	WI-18527	HT2695	1138	transcription factor ATF-a,	GCGCAACCGGGCTGC[A/G]GCCTCCCGCTGCCGC	S	A	G	A	A
				?
G313a9	WI-19158	HT0462	1948	platelet-derived growth	CTTGGGGTCTGGAGC[G/A]TTTGGGAAGGTGGTT	S	G	A	A	A
				factor, alpha polypeptide
				(GB:M21574), ?
G3168a1	WI-18528	HT27665	1364	zinc-finger protein	CATTGATAGCTTTGT[G/A]CTAAGCTTCCTTGGG	S	G	A	V	V
				(GB:U18543), ?
G3173a4	WI-18529	HT2772	729	ZNF74, zinc finger protein	GTTCCGCCAGAGCTC[C/T]TCCCTCACGCTGCAC	S	C	T	S	S
				74 (Cos52)
G3175a2	WI-18530	HT2776	3882	transcriptional regulator,	CATCTTGGAGCATGA[A/G]GAGGAAAATGAGGAA	S	A	G	E	E
				via glucocorticoid receptor,
				?
G3175a3	WI-18531	HT2776	4053	transcriptional regulator,	GGAGGATGAGCTGCC[C/T]TCCTGGATCATTAAG	S	C	T	P	P
				via glucocorticoid receptor,
				?
G303a2	WI-18283	HT3523	1012	POU6F1, POU domain, class	AAGGAGCTCAACTAC[G/A]ACCGTGAGGTAGTGC	M	G	A	D	N
				6, transcription factor 1
G3305a1	WI-18295	HT3549	791	AES, amino-terminal	CCAGCCCAGCTTGCA[G/A]GCCACCTCTAGCTTT	-	G	A
				enhancer of split
G3320a5	WI-18284	HT3622	471	BCL6, B-cell CLL/lymphoma 6	TAGAGCCCATAAAAC[G/A]GTCCTCATGGCCTGC	S	G	A	T	T
				(zinc finger protein 51)
G3220a6	WI-18285	HT3622	690	BCL6,B-cell CLL/lymphoma 6	TGTTGTGGACACTTG[C/T]CGGAAGTTTATTAAG	S	C	T	C	C
				(zinc finger protein 51)
G3358a7	WI-18286	HT4187	233	ETV5, ets variant gene 5	AAGTCCCTTTTATGG[T/C]CCCAGGGAAATCTCG	M	T	C	V	A
				(ets-related molecule)
G3358a8	WI-18287	HT4187	467	ETV5, ets variant gene 5	CCAAGATCAAACGGG[A/G]GCTGCACAGCCCCTC	M	A	G	E	G
				(ets-related molecule)
G3396a11	WI-18288	HT4491	1538	ZNF135, zinc finger protein	AGCCATAGCTCATCC[C/T]TTTCTAGATTTGACC	-	C	T
				135 (clone pHZ-17)
G3396a12	WI-18289	HT4491	1553	ZNF135, zinc finger protein	CTTTCTAGATTTGAC[C/T]CAATCATACACATGA	-	C	T
				135 (clone pHZ-17)
G3396a13	WI-18290	HT4491	1577	ZNF135, zinc finger protein	CACATGAGAAACGTA[C/A]ATTCATACACAAGCC	-	C	A
				135 (clone pHZ-17)
G3396a14	WI-18291	HT4491	1578	ZNF135, zinc finger protein	ACATGAGAAACGTAC[A/G]TTCATACACAAGCCT	-	A	G
				135 (clone pHZ-17)
G3396a15	WI-18292	HT4491	1582	ZNF135, zinc finger protein	GAGAAACGTACATTC[A/C]TACACAAGCCTTTTC	-	A	C
				135 (clone pHZ-17)
G3396a16	WI-18293	HT4491	1587	ZNF135, zinc finger protein	ACGTACATTCATACA[C/A]AAGCCTTTTCACACA	-	C	A
				135 (clone pHZ-17)
G3405a3	WI-18294	HT4519	378	ILF3, interleukin enhancer	CATGGTGTCCCACAC[G/A]GAGCGGGCGCTCAAA	S	G	A	T	T
				binding factor 3, 90kD
G345a6	WI-18402	HT1729	889	MSR1, macrophage scavenger	TTAATTCAAGGTCCT[C/G]CTGGACCCCCGGGTG	M	C	G	P	A
				receptor 1
G371a6	WI-18272	HT27943	1124	CRAT, carnitine	ATGGTGCCCCTGCCC[A/C]TGCCCAAGAAGCTGC	M	A	C	M	L
				acetyltransferase
G391a35	WI-19166	HT3630	5563	VWF, von Willebrand factor	CCCCAGCCAAATCGG[G/T]GATGCCTTGGGCTTT	S	G	T	G	G
G3941a8	WI-18172	HT3464	749	mannosidase, alpha,	TGGAGCAGGTGTGGC[G/A]GGCCAGCACCAGCCT	M	G	A	R	Q
				lysosomal, ?
G3941a9	WI-18173	HT3464	777	mannosidase, alpha,	CCTGAAGCCCCCGAC[C/T]GCGGACCTCTTCACT	S	C	T	T	T
				lysosomal, ?
G3956a1	WI-18296	HT1347	895	KRT18, keratin 18	GAGAGCACCACAGTG[G/A]TCACCACACAGTCTG	M	G	A	V	I
G3959a4	WI-18297	HT4490	2914	ADTB1, adaptin, beta 1	CCCCGGCCAGCGCCC[A/G]CCCCAGCCTTCTGCC	-	A	G
				(beta prime)
G3971a1	WI-18300	HT27832	152	CRYBB1, crystallin, beta B1	AGGGGAAGGGGGCCC[C/T]ACCTGCAGGAACATC	M	C	T	P	L
G3971a2	WI-18301	HT27832	227	CRYBB1, crystallin, beta B1	CCAGCGCCAAGGCGG[C/A]GGAACTGCCTCCTGG	M	C	A	A	E
G3971a3	WI-18302	HT27832	331	CRYBB1, crystallin, beta B1	AATCTGGCAGACCGT[G/A]GCTTCGACCGTGTGC	M	G	A	G	S
G3986a2	WI-18318	HT0708	580	TNNC1, troponin C, slow	GTCCTGGGGTTGGGG[A/G]GGGGGTCGGGGTCCC	-	A	G
G3986a3	WI-18319	HT0708	582	TNNC1, troponin C, slow	CCTGGGGTTGGGGAG[G/A]GGGTCGGGGTCCCAG	-	G	A
G4022a7	WI-18331	HT2426	812	TGM1, transglutaminase 1 (K	TGACCCCCGCAATGA[G/A]ATCTACATCCTCTTC	S	G	A	E	E
				polypeptide epidermal type
				I, protein-glutamine-gamma-
				glutamyltransferase)
G4022a8	WI-18332	HT2426	1645	TGM1, transglutaminase 1 (K	TTGTTTATGTGGAGG[A/G]GAAGGCCATCGGCAC	M	A	G	E	G
				polypeptide epidermal type
				I, protein-glutamine-gamma-
				glutamyltransferase)
G4022a9	WI-18333	HT2426	1905	TGM1, transglutaminase 1 (K	AATCACAGCAGCAGC[C/T]GCCGCACAGTGAAAC	M	C	T	R	C
				polypeptide epidermal type
				I, protein-glutamine-gamma-
				glutamyltransferase)
G4022a10	WI-18974	HT2426	1232	TGM1, transglutaminase 1 (K	CTGGGTCTTTGCTGG[C/A]GTGACCACCACAGTG	S	C	A	G	G
				polypeptide epidermal type
				I, protein-glutamine-gamma-
				glutamyltransferase)
G4038a18	WI-18350	HT4211	1275	LAMB3, laminin, beta 3	TGATCCGGATGGGGC[A/G]GTCGCAGGGGCTCCC	S	A	G	A	A
				(nicein (125kD), kalinin
				(140kD), BM600 (125kD))
G4038a19	WI-18351	HT4211	1429	LAMB3, laminin, beta 3	TGCAACATCCTGGGG[T/A]CCCGGGAGATGCCGT	M	T	A	S	T
				nicein (125kD), kalinin
				(140kD), BM600 (125kD))
G4038a20	WI-18352	HT4211	1820	LAMB3, laminin, beta 3	GTGACCAGTGCCAGC[G/A]AGGCTACTGCAATCG	M	G	A	R	Q
				(nicein (125kD), kalinin
				(140kD), BM600 (125kD))
G4042a1	WI-18992	HT1460	448	TNNC2, troponin C2, fast	CGGGGAGCACGTGAC[T/G]GACGAGGAGATCGAA	S	T	G	T	T
G4045a3	WI-18353	HT0652	1086	adducin, beta subunit, ?	TCGGATCAACCTGCA[G/A]AAGTGCCTTGGACCC	S	G	A	Q	Q
G4080a43	WI-18199	HT1396	2054	HSPG2, heparan sulfate	ACCTGGTGCTCTGAA[C/T]CAGCGCCAGGTCCAG	S	C	T	N	N
				proteoglycan 2 (perlecan)
G4080a44	WI-18200	HT1396	13032	HSPG2, heparan sulfate	GAGCTGGTCAGCGGC[C/A]GGTCCCCAGGTCCCA	S	C	A	R	R
				proteoglycan 2 (perlecan)
G4102a1	WI-18565	HT2458	1449	COL5A2, collagen, type V,	CCCAACGGGCTCTCC[G/A]GGTACCTCTGGTCCT	S	G	A	P	P
				alpha 2
G4102a2	WI-18566	HT2458	2039	COL5A2, collagen, type V,	CAGGAAATCCTGGAG[T/C]TCCTGGGCAAAGGGG	M	T	C	V	A
				alpha 2
G4106a2	WI-18355	HT2379	366	IVL, involucrin	CTTAAGCAGGAGAAA[A/G]CACAAAGGGATCAGC	M	A	G	T	A
G4106a3	WI-18356	HT2379	416	IVL, involucrin	AGAAGAGAAGAAGCT[C/T]TTAGACCAGCAACTG	S	C	T	L	L
G4112a3	WI-18357	HT4401	853	KIF5A, kinesin family	GGTGGACCTGGCAGG[G/A]AGTGAGAAGGTCAGC	S	G	A	G	G
				member 5A
G4112a4	WI-18358	HT4401	859	KIF5A, kinesin family	CCTGGCAGGGAGTGA[G/A]AAGGTCAGCAAGACT	S	G	A	E	E
				member 5A
G4112a5	WI-18359	HT4401	3103	KIF5A, kinesin family	CACATCTTCTGGCGG[C/T]CCCTTGGCTTCCTAC	S	C	T	G	G
				member 5A
G4114a2	WI-18360	HT4160	812	fibrinogen-like protein	AGGCACGTCTCGATG[G/A]GAGCACCAACTTCAC	M	G	A	G	E
				pT49, ?
G4122a2	WI-18362	HT97538	1209	myosin-I, ?	CGGAGCACCACGGTT[C/T]TCGGGCTCCTGGATA	M	C	T	L	F
G4122a3	WI-18363	HT97538	2437	myosin-I, ?	GGCGGCAGCTGCCCC[G/A]GAATGTCCTGGACAC	M	G	A	R	Q
G4122a4	WI-18364	HT97538	2609	myosin-I, ?	TGAGATCTTCAAGGG[C/A]AAGAAGGATAATTAC	S	C	A	G	G
G4122a5	WI-18365	HT97538	2745	myosin-I, ?	CCTGTTGTGAAATAC[G/A]ACCGCAAGGGCTACA	M	G	A	D	N
G4122a6	WI-18366	HT97538	3119	myosin-I, ?	CAAGAACGGGCACCT[G/T]GCTGTGGTCGCCCCA	S	G	T	L	L
G4124a3	WI-18367	HT0925	787	TGM3, transglutaminase 3 (E	GCCGGGACCCAAGGA[G/A]CTGGGACGGCAGCGT	M	G	A	S	N
				polypeptide, protein-
				glutamine-gamma-
				glutamyltransferase)
G4161a1	WI-18371	HT0853	977	KNS2, kinesin 2 (60-70kD)	TGCCCCTCTGCAAGC[A/C]GGCCCTGGAGGACCT	M	A	C	Q	P
G4218a2	WI-18380	HT1681	614	phosphatidyl-inositol	ACCGTGTCTCTTTGT[G/A]ATACAAACCACATCA	M	G	A	D	N
				glycan, class A, ?
G4227a4	WI-18381	HT1929	1027	proteoglycan 2, ?	GGGTGCCAGACCTGC[C/T]GCTACCTCCTGGTGA	M	C	T	R	C
G4255a5	WI-18382	HT2907	566	CRYAB, crystallin, alpha B	GAGTTCCACAGGAAA[T/C]ACCGGATCCCAGCTG	M	T	C	Y	H
G439a1	WI-18431	M67454	377	TNFRSF6, tumor necrosis	CCAATTCTGCCATAA[G/A]CCCTGTCCTCCAGGT	S	G	A	K	K
				factor receptor superfamily,
				member 6
G439a2	WI-18432	M67454	416	TNFRSF6, tumor necrosis	AGCTAGGGACTGCAC[A/G]GTCAATGGGGATGAA	S	A	G	T	T
				factor receptor superfamily,
				member 6
G4406a4	WI-18298	HT3564	901	ACPP, acid phosphatase,	CGCATGACACTACTG[T/C]GACTGGCCTACAGAT	M	T	C	V	A
				prostate
G441a5	WI-18478	M77349	267	TGFBI, transforming growth	TACCAAAGGAAAATC[T/C]GTGGCAAATCAACAG	M	T	C	C	R
				factor, beta-induced, 68kD
G411a6	WI-18479	M77349	984	TGFBI, transforming growth	AACAACCACATCTTG[A/G]AGTCAGCTATGTGTG	M	A	G	K	E
				factor, beta-induced, 68kD
G441a7	WI-18480	M77349	927	TGFBI, transforming growth	CCTAGTGAGACTTTG[A/G]ACCGTATCCTGGGCG	M	A	G	N	D
				factor, beta-induced, 68kD
G441a8	WI-18519	M77349	581	TGFBI, transforming growth	CCATATGGTGGGCAG[G/A]CGAGTCCTGACTGAT	S	G	A	R	R
				factor, beta-induced, 68kD
G441a9	WI-18520	M77349	708	TGFBI, transforming growth	CGGCTCCTGAAAGCC[G/A]ACCACCATGCAACCA	M	G	A	D	N
				factor, beta-induced, 68kD
G441a10	WI-18521	M77349	820	TGFBI, transforming growth	TTGAGACCCTTCGGG[C/T]TGCTGTGGCTGCATC	M	C	T	A	V
				factor, beta-induced, 68kD
G411a11	WI-18524	M77349	1640	TGFBI, transforming growth	ACTGACGGAGACCCT[C/T]AACCGGGAAGGAGTC	S	C	T	L	L
				factor, beta-induced, 68kD
G441a12	WI-18963	M77349	2148	TGFBI, transforming growth	GCTCTCCGCCAATTT[C/T]TCTCAGATTTCCACA	-	C	T
				factor, beta-induced, 68kD
G4411a3	WI-18299	HT97468	1387	acyl-CoA, ?	ACACAGTGTTGTCCC[G/A]AGCGCCGGGAGGCGT	-	G	A
G4417a17	WI-18690	HT0542	1238	AOAH, acyloxyacyl hydrolase	AAATCTATTTACCTT[C/A]GCTTATGGAAAAGAA	M	C	A	R	S
				(neutrophil)
G4417a18	WI-18691	HT0542	2088	AOAH, acyloxyacyl hydrolase	CTATGGGGGCTGCCA[C/T]GTCACAGGCCCAAAG	-	C	T
				(neutrophil)
G442a5	WI-18455	M94582	1262	IL8RA, interleukin 8	TGTGGTCACAGGAAG[C/T]AGAGGAGGCCACGTT	-	C	T
				receptor, alpha
G442a6	WI-18644	M94582	696	IL8RA, interleukin 8	TGTTACGGATCCTGC[C/T]CCAGTCCTTTGGCTT	M	C	T	P	L
				receptor, alpha
G442a7	WI-18645	M94582	789	IL8RA, interleukin 8	CCCACATGGGGCAGA[A/G]GCACCGGGCCATGCG	M	A	G	K	R
				receptor, alpha
G442a8	WI-18646	M94582	825	IL8RA, interleukin 8	TCTTTGCTGTCGTCC[T/C]CATCTTCCTGCTTTG	M	T	C	L	P
				receptor, alpha
G442a9	WI-18647	M94582	838	IL8RA, interleukin 8	CCTCATCTTCCTGCT[T/C]TGCTGGCTGCCCTAC	S	T	C	L	L
				receptor, alpha
G442a10	WI-19273	M94582	140	IL8RA, interleukin 8	TACAGCTCTACCCTG[C/T]CCCCTTTTCTACTAG	M	C	T	P	S
				receptor, alpha
G442a11	WI-19274	M94582	210	IL8RA, interleukin 8	AGTATTTTGTGGTCA[T/C]TATCTATGCCCTGGT	M	T	C	I	T
				receptor, alpha
G442a12	WI-19275	M94582	430	IL8RA, interleukin 8	GGTCTCACTCCTGAA[G/A]GAAGTCAACTTCTAT	S	G	A	K	K
				receptor, alpha
G4428a3	WI-18179	HT97524	1017	ADFP, adipose	TGTACCACAGAACAT[C/T]CAAGATCAAGCCAAG	S	C	T	I	I
				differentiation-related
				protein; adipophilin
G4442a4	WI-18695	HT2326	2651	ALD,	CCGGCCCCTGCCCCG[C/T]CCCCAAGCTCGGATC	-	C	T
				adrenoleukodystrophy/adrenom
				yeloneuropathy
G445a2	WI-18477	U40373	916	Human cell surface	GGCTTTGATTCTTGC[A/G]GTTTGCATTGCAGTC	S	A	G	A	A
				glycoprotein CD44 mRNA,
				complete cds., ?
G4451a1	WI-18696	HT0365	215	AKR1A1, aldo-keto reductase	CTGCTATCTACGGCA]A/G]TGAGCCTGAGATTGG	M	A	G	N	S
				family 1, member A1
				(aldehyde reductase)
G4455a1	WI-18697	HT0580	1124	ALDOB, aldolase B, fructose-	TATGAAGCGGGCCAT[G/A]GCTAACTGCCAGGCG	M	G	A	M	I
				bisphosphate
G4456a2	WI-18698	HT0626	496	ALDOC, aldolase C, fructose-	TCAAGGGCTGGATGG[G/A]CTCTCAGAACGCTGT	S	G	A	G	G
				bisphosphate
G446a9	WI-18648	U64198	1354	IL12RB2, interleukin 12	ATTTCAAAAGGCTTC[C/T]GTGAGCAGATGTACC	S	C	T	S	S
				receptor, beta 2
G446a10	WI-18649	U64198	2245	IL12RB2, interleukin 12	CACAGAGGAAAAGGG[G/A]AGCATTTTAATTTCA	S	G	A	G	G
				receptor, beta 2
G446a11	WI-18650	U64198	2962	IL12RB2, interleukin 12	GCTGGAGAGCAGGGG[C/T]TCCGACCCAAAGCCA	S	C	T	G	G
				receptor, beta 2
G446a12	WI-18651	U64198	2977	IL12RB2, interleukin 12	CTCCGACCCAAAGCC[A/C]GAAAACCCAGCCTGT	S	A	C	P	P
				receptor, beta 2
G446a13	WI-18652	U64198	2997	IL12RB2, interleukin 12	ACCCAGCCTGTCCCT[G/A]GACGGTGCTCCCAGC	N	G	A	W	*
				receptor, beta 2
G446a14	WI-19276	U64198	909	IL12RB2, interleukin 12	TCAATTCTCAAGTCA[C/T]AGGTCTTCCCCTTGG	M	C	T	T	I
				receptor, beta 2
G446a15	WI-19277	U64198	1711	IL12RB2, interleukin 12	GGCAAGAGGAAAAAT[T/C]CTCCACTATCAGGTG	S	T	C	I	I
				receptor, beta 2
G4468a2	WI-18325	HT4305	1149	FUT7, fucosyltransferase 7	GGTTGGTTTCAGGCC[T/A]GAGATCCGCTGGCCG	N	T	A	*	R
				(alpha (1,3)
				fucosyltransferase)
G4468a3	WI-18326	HT4305	1157	FUT7, fucosyltransferase 7	TCAGGCCTGAGATCC[G/C]CTGGCCGGGGGAGGT	-	G	C
				(alpha (1,3)
				fucosyltransferase)
G4473a4	WI-18327	HT1352	400	FUCA1, fucosidase, alpha-L-	GGCGCCAAGTATGTA[G/T]TTTTGACGACAAAGC	M	G	T	V	F
				1, tissue
G4488a5	WI-18181	HT1559	684	SLC4A2, solute carrier	AGGAGGCGGAGGCGG[A/T]GGCGGTGGCGGTGGC	M	A	T	E	V
				family 4, anion exchanger,
				member 2 (erythrocyte
				membrane protein band 3-like
				1)
G4488a6	WI-18182	HT1559	702	SLC4A2, solute carrier	CGGTGGCGGTGGCCA[G/C]TGGCACAGCAGGGGG	M	G	C	S	T
				family 4, anion exchanger,
				member 2 (erythrocyte
				membrane protein band 3-like
				1)
G4488a7	WI-18329	HT1559	3837	SLC4A2, solute carrier	GAGGGACCGATGGAC[G/A]AGGGGACAGGCTGGT	-	G	A
				family 4, anion exchanger,
				member 2 (erythrocyte
				membrane protein band 3-like
				1)
G450A2	WI-18503	X85740	649	CCR4, chemokine (C-C motif)	TGACTTATGGGGTCA[T/C]CACCAGTTTGGCTAC	M	T	C	I	T
				receptor 4
G450a3	WI-18677	X85740	1111	CCR4, chemokine (C-C motif)	TTTTTCTGGGGGAGA[A/T]ATTTCGCAAGTACAT	M	A	T	K	I
				receptor 4
G4502a14	WI-18334	HT4840	269	ASS, argininosuccinate	TCATTGAGGATGTCA[G/T]CAGGGAGTTTGTGGA	M	G	T	S	I
				synthetase
G4502a15	WI-18335	HT4840	1227	ASS, argininosuccinate	GCAGGGTGATTATGA[G/T]CCAACTGATGCCACC	M	G	T	E	D
				synthetase
G4526a3	WI-18538	HT4994	672	ATP5D, ATP synthase, H+	AGCTCCTGGGGTCCC[G/C]GCCACCTGGGGAAGC	-	G	C
				transporting, mitochondrial
				F1 complex, delta subunit
G4548a4	WI-18539	HT1574	3814	ATPase, Ca2+ transporting,	TTAGCTGAGGACCCT[C/G]TCGCCTGCCCGCCCG	-	C	G
				plasma membrane, isoform 2,
				?
G4548a5	WI-18701	HT1574	3427	ATPase, Ca2+ transporting,	GGAGATCGACCACGC[G/A]GAGCGGGAGCTGCGG	S	G	A	A	A
				plasma membrane, isoform 2,
				?
G4549a5	WI-18186	HT1346	1519	ATP2B4, ATPase, Ca++	CATGTCTGCTCTCAC[G/A]GTTTTCATCCTGATT	S	G	A	T	T
				transporting, plasma
				membrane 4
G4549a6	WI-18187	HT1346	1612	ATP2B4, ATPase, Ca++	CATCTACATCCAGTA[C/T]TTTGTCAAGTTCTTC	S	C	T	Y	Y
				transporting, plasma
				membrane 4
G4549a7	WI-18188	HT1346	2317	ATP2B4, ATPase, Ca++	CCGGACTATCTGCAT[A/G]GCTTACCGGGACTTC	M	A	G	I	M
				transporting, plasma
				membrane 4
G4549a8	WI-18189	HT1346	2596	ATP2B4, ATPase, Ca++	CCGGCTCATCCGCAA[C/T]GAGAAAGGCGAGGTA	S	C	T	N	N
				transporting, plasma
				membrane 4
G4549a9	WI-18190	HT1346	4067	ATP2B4, ATPase, Ca++	TTTCCATTTTCGTCT[G/A]TCCCATCTATGAGGT	-	G	A
				transporting, plasma
				membrane 4
G4549a10	WI-18191	HT1346	4101	ATP2B4, ATPase, Ca++	GATGGGACTTTTCAT[C/T]GTCACGTCAGCTGCT	-	C	T
				transporting, plasma
				membrane 4
G4549a11	WI-18540	HT1346	2983	ATP2B4, ATPase, Ca++	AGCCTTCACTGGAGC[C/T]TGTATCACTCAGGAT	S	C	T	A	A
				transporting, plasma
				membrane 4
G4549a12	WI-18541	HT1346	3805	ATP2B4, ATPase, Ca++	GACCCACCCTGAATT[C/T]GCCATAGAGGAGGAG	S	C	T	F	F
				transporting, plasma
				membrane 4
G4593a6	WI-18303	HT97373	1207	BARD1, BRCA1 associated	TGGTACATCAGGGAG[G/C]AAAAACAGTAACATG	M	G	C	R	S
				RING domain 1
G4593a7	WI-18304	HT97373	1252	BARD1, BRCA1 associated	TAGTCTTTCACCAGG[T/G]ACACCACCTTCTACA	S	T	G	G	G
				RING domain 1
G4593a8	WI-18692	HT97373	2045	BARD1, BRCA1 associated	ATTCCTGAAGGTCCA[C/T]GCAGAAGCAGGCTCA	M	C	T	R	C
				RING domain 1
G4597a2	WI-18693	HT4270	254	CDH11, cadherin 11 (OB-	GGGGCACCTGCGGCC[C/T]TCCTTCCATGGGCAC	S	C	T	P	P
				cadherin, osteoblast)
G4597a3	WI-18694	HT4270	919	CDH11, cadherin 11 (OB-	GGACAACCAAAGTGA[C/T]GATCACACTGACCGA	M	C	T	T	M
				cadherin, osteoblast)
G4598a1	WI-18966	HT4271	295	CDH12, cadherin 12 (N-	GTGCTGGAAGAATAC[G/A]TGGGCTCCGAGCCTC	M	G	A	V	M
				cadherin 2)
G4599a2	WI-18967	HT4273	2520	CDH13, cadherin 13, H-	GGACTGCAACGCGGC[G/A]GGGGCCCTGCGCTTC	S	G	A	A	A
				cadherin (heart)
G4601a1	WI-18968	HT4274	617	CDH4, cadherin 4, R-	CAAAGACAATGACAT[C/T]CCCATCCGGTACAGC	S	C	T	I	I
				cadherin (retinal)
G4601a2	WI-18969	HT4274	824	CDH4, cadherin 4, R-	CTACGTCATCGACAT[G/A]AATGACAACCACCCT	M	G	A	M	I
				cadherin (retinal)
G4601a3	WI-18970	HT4274	875	CDH4, cadherin 4, R-	CAACTGCTCCGTGGA[C/T]GAGGGCTCCAAGCCA	S	C	T	D	D
				cadherin (retinal)
G4603a1	WI-18971	HT4275	176	CDH8, cadherin 8	CCAAAAGAGGCTGGG[T/C]TTGGAATCAAATGTT	M	T	C	V	A
G4603a2	WI-18972	HT4275	481	CDH8, cadherin 8	AATGACAATGCACCA[G/C]AGTTTGTTAATGGAC	M	G	C	E	Q
G4606a1	WI-18815	HT27350	1923	CDH6, cadherin 6, K-	CATGCAATCCTGCCA[T/C]GCGGAGGCGCTCATC	S	T	C	H	H
				cadherin (fetal kidney)
G4606a2	WI-18816	HT27350	2136	CDH6, cadherin 6, K-	GGACACCCAGGCTTT[T/C]GATATCGGCACCCTG	S	T	C	F	F
				cadherin (fetal kidney)
G4606a3	WI-18973	HT27350	2396	CDH6, cadherin 6, K-	AGTCAGTGACCACGG[A/C]TGCAGATCAAGACTA	M	A	C	D	A
				cadherin (fetal kidney)
G4614a6	WI-18699	HT4835	209	S100A3, S100 calcium-	GCTGCAGAAGGAGCT[G/A]GCCACCTGGACCCCG	S	G	A	L	L
				binding protein A3
G4614a7	WI-18700	HT4835	453	S100A3, S100 calcium-	CACACCCCCTCCTAC[C/T]CTCTCTCCTGTACCC	-	C	T
				binding protein A3
G4644a10	WI-18542	HT1736	1148	CPS1, carbamoyl-phosphate	TATGCCTTGGACAAC[A/G]CCCTCCCTGCTGGCT	M	A	G	T	A
				synthetase 1, mitochondrial
G4644a11	WI-18543	HT1736	1150	CPS1, carbamoyl-phosphate	TGCCTTGGACAACAC[C/T]CTCCCTGCTGGCTGG	S	C	T	T	T
				synthetase 1, mitochondrial
G4674a5	WI-18330	HT1393	1838	CDC25B, cell division cycle	CAGCTGCCCTATGGG[C/T]CTGCCGGGCTGAGGG	-	C	T
				25B
G4691a13	WI-18336	HT97602	234	CMKBR9, chemokine (C-C	GGTCTTGCTCCGTTA[C/T]GTGCCTCGCAGGCGG	S	C	T	Y	Y
				motif) receptor 9
G4691a14	WI-18337	HT97602	680	CMKBR9, chemokine (C-C	GGTTTCTCCTTCCAC[T/C]CCTTGCCATGATCTT	M	T	C	L	P
				motif) receptor 9
G4726a6	WI-18975	HT48614	1146	AOC3, amine oxidase, copper	GTGTCCAGGGAAGTC[G/A]AGTGGCCTCCTCACT	M	G	A	R	Q
				containing 3 (vascular
				adhesion protein 1)
G4726a7	WI-18976	HT48614	1437	AOC3, amine oxidase, copper	CCCCCAAGACAATAC[G/A]TGATGCCTTTTGTGT	M	G	A	R	H
				containing 3 (vascular
				adhersion protein 1)
G4726a8	WI-18977	HT48614	1481	AOC3, amine oxidase, copper	CAGGGCCTCCCCCTG[C/T]GGCGACACCACTCAG	M	C	T	R	W
				containing 3 (vascular
				adhesion protein 1)
G4732a1	WI-18978	HT48529	1697	DOCK1, dedicator of cyto-	CTATAAGGCCGAAGC[G/A]AAGAAGCTGGAAGAT	S	G	A	A	A
				kinesis 1
G4732a2	WI-18979	HT48529	2667	DOCK1, dedicator of cyto-	CTGGAGGCCTGCTGT[C/T]AGCTGCTCAGCCACA	N	C	T	Q	*
				kinesis 1
G4732a3	WI-18980	HT48529	2792	DOCK1, dedicator of cyto-	CATTTCCATGGGACG[A/G]GATTCTGAACTCATT	S	A	G	R	R
				kinesis 1
G4732a4	WI-18981	HT48529	3374	DOCK1, dedicator of cyto-	GTGTGAATTCCATTC[G/A]ACCCGAAGCTTCCAA	S	G	A	S	S
				kinesis 1
G4732a5	WI-18982	HT48529	3398	DOCK1, dedicator of cyto-	CTTCCAAATGTTTGA[A/T]AATGAGATCATCACC	M	A	T	E	D
				kinesis 1
G4732a6	WI-18983	HT48529	4211	DOCK1, dedicator of cyto-	CGACGATATTAAAAA[C/T]TCTCCTGGCCAGTAT	S	C	T	N	N
				kinesis 1
G4732a7	WI-18984	HT48529	4505	DOCK1, dedicator of cyto-	CCTGGAGAATGCCAT[C/T]GAGACCATGCAGCTG	S	C	T	I	I
				kinesis 1
G4732a8	WI-18985	HT48529	5345	DOCK1, dedicator of cyto-	TCCAGTTACACCAAG[A/G]GCCAAGCTCAGCTTC	S	A	G	R	R
				kinesis 1
G4732a9	WI-18986	HT48529	5400	DOCK1, dedicator of cyto-	AACGGCATGACGGGG[G/A]CGGACGTGGCCGATG	M	G	A	A	T
				kinesis 1
G4732a10	WI-18987	HT48529	5558	DOCK1, dedicator of cyto-	GCCCAGCAAAACTCC[G/A]CCTCCTCCCCCTCCA	S	G	A	P	P
				kinesis 1
G4732a11	WI-18988	HT48529	5592	DOCK1, dedicator of cyto-	ACAACTCGCAAGCAG[A/G]CATCGGTGGACTCTG	M	A	G	T	A
				kinesis 1
G4732a12	WI-18989	HT48529	5606	DOCK1, dedicator of cyto-	GACATCGGTGGACTC[T/C]GGGATCGTGCAGTGA	S	T	C	S	S
				kinesis 1
G4732a13	WI-18990	HT48529	5623	DOCK1, dedicator of cyto-	GGATCGTGCAGTGAC[A/G]TCGCAAGGCTCTCTG	-	A	G
				kinesis 1
G4732a14	WI-18991	HT48529	5631	DOCK1, dedicator of cyto-	CAGTGACATCGCAAG[G/C]CTCTCTGGAAAGAGT	-	G	C
				kinesis 1
G4754a1	WI-18397	HT1855	1047	CYP2C8, cytochrome P450	ACATGCCTTACACTG[A/G]TGCTGTAGTGCACGA	M	A	G	D	G
				subfamily IIC (mephenytoin 4-
				hydroxylase), polypeptide 8
G4788a4	WI-18354	HT28249	1875	DSC3, desmocollin 3	ATCCTGATGAACCTG[T/C]CCATGGAGCTCCATT	M	T	C	V	A
G4827a2	WI-18183	HT97477	223	elongation, ?	AGCTCCAGCGGGTCC[C/G]CGGCAAACTCCTTCC	M	C	G	P	A
G4827a3	WI-18184	HT97477	489	elongation, ?	CCAGCAGTGGAAGGG[C/A]GCCTCCAACTACGTG	S	C	A	G	G
G4828a1	WI-18702	HT4894	170	elongation factor Ts,	CACAAGGAGGCCCAG[A/T]AGGAGGGCTGGAGCA	N	A	T	K	*
				mitochondrial, ?
G4828a2	WI-18703	HT4894	201	elongation factor Ts,	AAGCTGCCAAGCTCC[A/G]AGGGAGGAAGACCAA	M	A	G	Q	R
				mitochondrial, ?
G4828a3	WI-18704	HT4894	334	elongation factor Ts,	GGTCCAGCAAGTAGC[C/T]CTTGGAACCATGATG	S	C	T	A	A
				mitochondrial, ?
G5110a1	WI-18919	HT3433	1916	HK2, hexokinase 2	CATGGATAAGCTACA[A/T]ATCAAAGACAAGAAG	M	A	T	Q	H
G5110a2	WI-18920	HT3433	2243	HK2, hexokinase 2	CATGGTGGAAGGCGA[T/C]GAGGGGCGGATGTGT	S	T	C	D	D
G5110a3	WI-18921	HT3433	2452	HK2, hexokinase 2	AGGAGCTGCTCTTTG[G/C]GGGGAAGCTCAGCCC	M	G	C	G	A
G5110a4	WI-18922	HT3433	2594	HK2, hexokinase 2	GACTCAGGAGGACTG[C/T]GTGGCCACTCACCGG	S	C	T	C	C
G5110a5	WI-18923	HT3433	2649	HK2, hexokinase 2	TCCGCCAGCCTGTGC[G/T]CAGCCACCCTGGCCG	M	G	T	A	S
G5110a6	WI-18924	HT3433	2980	HK2, hexokinase 2	AGGTAGAAATGGAGC[G/A]AGGTCTGAGCAAGGA	M	G	A	R	Q
G5110a7	WI-18925	HT3433	3566	HK2, hexokinase 2	GGAGGAGATGCGCAA[C/T]GTGGAACTGGTGGAA	S	C	T	N	N
G5110a8	WI-18926	HT3433	3698	HK2, hexokinase 2	GCTTTCACTCAACCC[C/G]GGCAAGCAGAGGTTC	S	C	G	P	P
G5110a9	WI-18927	HT3433	3788	HK2, hexokinase 2	CACCAAGCGTGGACT[A/G]CTCTTCCGAGGCCGC	S	A	G	L	L
G5110a10	WI-18928	HT3433	4021	HK2, hexokinase 2	CCGCTGTGGTGGACA[G/A]GATACGAGAAAACCG	M	G	A	R	K
G5188a1	WI-18740	HT33638	1144	interferon-related protein	GGGCATGCACCACCA[C/T]CTCCAGAACAATGAG	S	C	T	H	H
				SM15, ?
G5188a2	WI-18741	HT36638	1311	interferon-related protein	GTGTGCGGGACAAGC[G/A]GGCAGACATCCTGTG	M	G	A	R	Q
				SM15, ?
G5191a1	WI-18904	HT3774	2395	interleukin-2 receptor,	GAAGGGGTCGCACCT[C/T]TCTCACAGGCCCCCT	M	C	T	L	F
				alpha chain, kappa B binding
				protein, ?
G5191a2	WI-18905	HT3774	3015	interleukin-2 receptor,	GGGGCCAGTGAAGGG[C/A]GTGTTTGACAAGGAG	S	C	A	G	G
				alpha chain, kappa B binding
				protein, ?
G5191a3	WI-18906	HT3774	3729	interleukin-2 receptor,	CAGTTCTCAGGCTGC[C/T]GCCCGGGTCGTGAGC	S	C	T	A	A
				alpha chain, kappa B binding
				protein, ?
G5191a4	WI-18907	HT3774	4629	interleukin-2 receptor,	TGCCACGATCCGCAT[C/T]GTGCAGGGACTGGGA	S	C	T	I	I
				alpha chain, kappa B binding
				protein, ?
G5213a1	WI-18213	HT4528	168	CDKN1B, cyclin-dependent	CATGGAAGAGGCGAG[C/T]CAGCGCAAGTGGAAT	S	C	T	S	S
				kinase inhibitor 1B (p27,
				Kip1)
G5213a2	WI-18214	HT4528	326	CDKN1B, cyclin-dependent	AGGAGAGCCAGGATG[T/G]CAGCGGGAGCCGCCC	M	T	G	V	G
				kinase inhibitor 1B (p27,
				Kip1)
G5217a1	WI-18932	HT3714	5845	LCT, lactase	AGTTTCTTCATCTAT[C/G]TTTACCGGCCACCAA	—	C	G
G5235a1	WI-18898	HT2457	160	SPN, sialophorin (gpL115,	CTCTGGGGAGCACAA[C/T]AGCAGTGCAGACACC	M	C	T	T	I
				leukosialin, CD43)
G5235a2	WI-18899	HT2457	372	SPN, sialophorin (gpL115,	CCTTTACCTGAGCCA[A/G]CAACCTACCAGGAAG	M	A	G	T	A
				leukosialin, CD43)
G5235a3	WI-18900	HT2457	932	SPN, sialophorin (gpL115,	CCTGCTGTGGCGCCG[G/A]CGGCAGAAGCGGCGG	S	G	A	R	R
				leukosialin, CD43)
G5235a4	WI-18901	HT2457	974	SPN, sialophorin (gpL115,	CGTGCTGAGCAGAGG[C/T]GGCAAGCGTAACGGG	S	C	T	G	G
				leukosialin, CD43)
G5235a5	WI-18902	HT2457	1110	SPN, sialophorin (gpL115,	GAGGGGTCTAGCCGT[C/G]GGCCCACGCTCACCA	M	C	G	R	G
				leukosialin, CD43)
G5235a6	WI-18903	HT2457	1231	SPN, sialophorin (gpL115,	AGCCACTGGTGGCCA[G/C]TGAGGATGGGGCTGT	M	G	C	S	T
				leukosialin, CD43)
G5237a1	WI-18933	HT3964	641	SORD, sorbitol	TGCCTGCAGGAGAGG[C/T]GGAGTTACCCTGGGA	S	C	T	G	G
				dehydrogenase
G5237a2	WI-18934	HT3964	672	SORD, sorbitol	CACAAGGTCCTTGTG[T/C]GTGGAGCTGGGCCAA	M	T	C	C	R
				dehydrogenase
G5237a3	WI-18935	HT3964	827	SORD, sorbitol	CAAGGAGAGCCCTCA[G/A]GAAATCGCCAGGAAA	S	G	A	Q	Q
				dehydrogenase
G5237a4	WI-18936	HT3964	853	SORD, sorbitol	GGAAAGTAGAAGGTC[T/A]GCTGGGGTGCAAGCC	M	T	A	L	Q
				dehydrogenase
G5237a5	WI-18937	HT3964	914	SORD, sorbitol	GGCCTCCATCCAGGC[G/A]GGCATCTACGCCACT	S	G	A	A	A
				dehydrogenase
G5237a6	WI-18938	HT3964	943	SORD, sorbitol	CTCGCTCTGGTGGGA[C/A]CCTCGTGCTTGTGGG	M	C	A	T	N
				dehydrogenase
G5254a1	WI-18577	HT1581	235	BSG, basigin	TGGCTGAAGGGGGGC[G/T]TGGTGCTGAAGGAGG	M	G	T	V	L
G5254a2	WI-18578	HT1581	252	BSG, basigin	GGTGCTGAAGGAGGA[C/T]GCGCTGCCCGGCCAG	S	C	T	D	D
G5254a3	WI-18579	HT1581	291	BSG, basigin	GTTCAAGGTGGACTC[C/G]GACGACCAGTGGGGA	S	C	G	S	S
G5254a4	WI-18580	HT1581	384	BSG, basigin	TCCCAGAGTGAAGGC[C/T]GTGAAGTCGTCAGAA	S	C	T	A	A
G5254a5	WI-18581	HT1581	429	BSG, basigin	GGAGACGGCCATGCT[G/A]GTCTGCAAGTCAGAG	S	G	A	L	L
G5254a6	WI-18582	HT1581	898	BSG, basigin	GACGCTCCCTGCTCC[G/A]CGTCTGCGCCGCCGC	—	G	A
G5256a1	WI-18892	HT2001	170	CAPG, capping protein	CAAGAGAACCAGGGC[G/A]TCTTCTTCTCGGGGG	M	G	A	V	I
				(actin filament), gelsolin-
				like
G5256a2	WI-18893	HT2001	307	CAPG, capping protein	TGTGCACCTCAACAC[G/A]CTGCTGGGAGAGCGG	S	G	A	T	T
				(actin filament), gelsolin-
				like
G5256a3	WI-18894	HT2001	862	CAPG, capping protein	CGCTGACTCCAGCCC[C/A]TTTGCCCTTGAACTG	S	C	A	P	P
				(actin filament), gelsolin-
				like
G5257a1	WI-18895	HT27995	204	macrophage differentiation-	ATTCCTCATTGTTCC[G/A]GCCATCGTGGGCAGT	S	G	A	P	P
				associated protein, ?
G5257a2	WI-18896	HT27995	219	macrophage differentiation-	GGCCATCGTGGGCAG[T/C]GCCCTCCTCCATCGG	S	T	C	S	S
				associated protein, ?
G5257a3	WI-18897	HT27995	609	macrophage differentiation-	AATGAACAACACCGA[T/C]GGACTTCAGGAACTT	S	T	C	D	D
				associated protein, ?
G5333a1	WI-18593	HT97206	307	FUT8, fucosyltransferase 8	TGAACGCTTAAAACA[G/A]CAGAATGAAGACTTG	S	G	A	Q	Q
				(alpha (1,6)
				fucosyltransfease)
G5333a2	WI-18594	HT97206	443	FUT8, fucosyltransferase 8	CAGATTGAAAATTAC[A/C]AGAAACAGACCAGAA	M	A	C	K	Q
				(alpha (1,6)
				fucosyltransferase)
G538a11	WI-19456	M55531	677	SLC2A5, solute carrier	TGGGGCTGACCGGGG[T/A]CCCCGCGGCGCTGCA	M	T	A	V	D
				family 2 (facilitated
				glucose transporter), member
				5
G5418a1	WI-18948	HT3037	260	PBP, prostatic binding	GGTTAAGAATAGACC[C/T]ACCAGCATTTCGTGG	S	C	T	P	P
				protein
G5418a2	WI-18949	HT3037	394	PBP, prostatic binding	TCAACATGAAGGGCA[A/G]TGACATCAGCAGTGG	M	A	G	N	S
				protein
G5418a3	WI-18950	HT3037	164	PBP, prostatic binding	CCTGCAAGAAGTGGA[C/T]GAGCAGCCGCAGCAC	S	C	T	D	D
				protein
G5437a1	WI-18599	HT27771	126	PGD, phosphogluconate	TGTCTCCAAAGTTGA[C/T]GATTTCTTGGCCAAT	S	C	T	D	D
				dehydrogenase
G5437a2	WI-18600	HT27771	738	PGD, phosphogluconate	TCTCAAGTTCCAAGA[C/T]ACCGATGGCAAACAC	S	C	T	D	D
				dehydrogenase
G5437a3	WI-18601	HT27771	742	PGD, phosphogluconate	AAGTTCCAAGACACC[G/A]ATGGCAAACACCTGC	M	G	A	D	N
				dehydrogenase
G5475a1	WI-18908	HT97315	542	?, ?	AAAGCTGTGCTTGAT[G/A]GACTTGATGTGCTCC	M	G	A	G	R
G5475a2	WI-18909	HT97315	559	?, ?	ACTTGATGTGCTCCT[T/C]GCCCAGGAGGTTCGC	S	T	C	L	L
G5475a3	WI-18910	HT97315	1001	?, ?	AAATTTTCTCCTTAC[C/T]TGGGCCAGATGATTA	S	C	T	L	L
G5475a4	WI-18911	HT97315	1022	?, ?	CAGATGATTAATCTG[C/T]GTAGACTCCTCCTCT	M	C	T	R	C
G5475a5	WI-18912	HT97315	1498	?, ?	TTCCATCTCCATATC[T/C]GCCTTGCAGAGTCTC	S	T	C	S	S
G5475a6	WI-18913	HT97315	1762	?, ?	CTGTTTCATGCCTAA[C/T]TAGCTGGGTGCACAT	S	C	T	N	N
G5479a1	WI-18951	HT0761	594	prosaposin, ?	CCTCAGGACGGCCCC[C/T]GCAGCAAGCCCCAGC	M	C	T	R	C
G5479a2	WI-18952	HT0761	608	prosaposin, ?	CCGCAGCAAGCCCCA[G/T]CCAAAGGATAATGGG	M	G	T	Q	H
G5479a3	WI-18953	HT0761	1490	prosaposin, ?	TGGAGCCTGCCCCTC[G/A]GCCCATAAGCCCTTG	S	G	A	S	S
G5487a1	WI-18939	HT97615	478	PI12, protease inhibitor 12	ATGAAAAAATATTTT[A/T]ATGCAGCAGTAAATC	M	A	T	N	Y
				(neuroserpin)
G5487a2	WI-18940	HT97615	657	PI12, protease inhibitor 12	GGGGAACTGGAAGTC[G/A]CAGTTTAGGCCTGAA	S	G	A	S	S
				(neuroserpin)
G5497a1	WI-18587	HT1286	1624	?, ?	AACAACAAGGGACCC[G/A]TCAAGGTCGTGGTGG	M	G	A	V	I
G5498a1	WI-18215	HT4254	830	GSK3B, glycogen synthase	GGGATAGTGGTGTGG[A/G]TCAGTTGGTAGAAAT	M	A	G	D	G
				kinase 3 beta
G5554a1	WI-18941	HT4883	1225	PTPRJ, protein tyrosine	GAAGGTGGCTTGGAT[G/A]CCAGCAATACAGAGA	M	G	A	M	I
				phosphatase, receptor type,
				J
G5554a2	WI-18942	HT4883	1326	PTPRJ, protein tyrosine	CCGGCCCAGCAGTCCC[G/A]AGACACGGAAGTCCT	M	G	A	R	Q
				phosphatase, receptor type,
				J
G5554a3	WI-18943	HT4883	1463	PTPRJ, protein tyrosine	ATTCAGGTTTTTGAC[G/A]TCACCGCTGTGAACA	M	G	A	V	I
				phosphatase, receptor type,
				J
G5554a4	WI-18944	HT4883	2219	PTPRJ, protein tyrosine	TCCACTGCACAGTAC[A/G]CACGGCCCAGCAATG	M	A	G	T	A
				phosphatase, receptor type,
				J
G5554a5	WI-18945	HT4883	2289	PTPRJ, protein tyrosine	CTTTAAGTTGGCAGA[A/T]CTTTGATGACGCCTC	M	A	T	N	I
				phosphatase, receptor type,
				J
G5554a6	WI-18946	HT4883	3997	PTPRJ, protein tyrosine	CACTGACCTGCTCAT[C/T]AACTTCCGGTACCTC	S	C	T	I	I
				phosphatase, receptor type,
				J
G5554a7	WI-18947	HT4883	4321	PTPRJ, protein tyrosine	CTATGAAAACCTTGC[G/A]CCCGTGACCACATTT	S	G	A	A	A
				phosphatase, receptor type,
				J
G5613a1	WI-18589	HT97193	664	rhodanese, ?	GACTCGGGCCATATC[C/T]GTGGTGCCGTCAACA	M	C	T	R	C
G5613a2	WI-18590	HT97193	816	rhodanese, ?	AGTCACCGCCTGCCA[C/T]GTGGCCTTGGCTGCC	S	C	T	H	H
G5638a1	WI-18608	HT3181	709	SHMT2, serine	CAAGGTGATTCCCTC[G/A]CCTTTCAAGCACGCG	S	G	A	S	S
				hydroxymethyltransferase 2
				(mitochondrial)
G5638a2	WI-18609	HT3181	724	SHMT2, serine	GCCTTTCAAGCACGC[G/A]GACATCTGCACCACC	S	G	A	A	A
				hydroxymethyltransferase 2
				(mitochondrial)
G5638a3	WI-18610	HT3181	880	SHMT2, serine	GCTGTTCCCATCCCT[T/G]CAGGGGGGCCCCCAC	S	T	G	L	L
				hydroxymethyltransferase 2
				(mitochondrial)
G5638a4	WI-18761	HT3181	1267	SHMT2, serine	TATAGATGAAGGGGT[C/T]AACATTGGCTTAGAG	S	C	T	V	V
				hydroxymethyltransferase 2
				(mitochondrial)
G5639a1	WI-18611	HT4498	1965	SRPK1, SFRS protein kinase	GAAGTATGAGTGGTC[T/G]CAGGAAGAGGCAGCT	S	T	G	S	S
				1
G5663a1	WI-18606	HT4409	1831	RAB8IP, Rab8 interacting	GACACCAAAGGCTGC[T/C]TGCAGTGTCGTGTGG	S	T	C	L	L
				protein (GC kinase)
G5663a2	WI-18606	HT4409	2606	RAB8IP, Rab8 interacting	CCAGGCCCTGGCCCT[G/T]CTGGGGCTGAAGGTC	—	G	T
				protein (GC kinase)
G5664a1	WI-18753	HT2748	1130	CDK6, cyclin-dependent	TTAAGCTGATCCTGC[G/A]GAGAACACCCTTGGT	—	G	A
				kinase 6
G5678a1	WI-18763	HT4978	498	sialyltransferase, SThM, ?	TATCCGGTGTGCCGT[G/C]GTGGGCAACGGAGGC	S	G	C	V	V
G5678a2	WI-18764	HT4978	527	sialyltransferase, SThM, ?	GCATTCTGAATGGGT[C/T]CCGCCAGGGTCCCAA	M	C	T	S	F
G570a1	WI-19120	L13288	538	?, ?	GACCGGCTACACCAT[C/T]GGCTACGGCCTGTCC	S	C	T	I	I
G570a2	WI-19121	L13288	894	?, ?	GCTGGGGGGTACCCA[G/A]CACATTCACCATGGT	M	G	A	S	N
G570a4	WI-19399	L13288	1278	?, ?	TCCTCAATGGTGAGG[T/C]GCAGGCGGAGCTGAG	M	T	C	V	A
G570a5	WI-19400	L13288	1308	?, ?	GGCGGAAGTGGCGGC[G/A]CTGGCACCTGCAGGG	M	G	A	R	H
G570a6	WI-19401	L13288	1354	?, ?	CCCCAAATACCGGCA[C/T]CCGTCGGGAGGCAGC	S	C	T	H	H
G5709a5	WI-18246	HT3731	820	SMPD1, sphingomyelin	CGGAGCCCTGTGGCA[C/T]GCCCTGCCGTCTGGC	M	C	T	T	M
				phosphodiesterase 1, acid
				lysosomal (acid
				sphingomyelinase)
G5788a1	WI-18556	HT1698	163	EIF4A1, eukaryotic	CCGTGGCATCTACGC[C/G]TATGGTTTTGAGAAG	S	C	G	A	A
				translation initiation
				factor 4A, isoform 1
G5788a2	WI-18557	HT1698	283	EIF4A1, eukaryotic	CACATTTGCCATATC[G/A]ATTCTGCAGCAGATT	S	G	A	S	S
				translation initiation
				factor 4A, isoform 1
G5790a1	WI-18874	HT3679	1663	EIF4B, eukaryotic	TAGCCGTGGTCCAGG[A/C]GACGGAGGGAACAGA	S	A	C	G	G
				translation initiation
				factor 4B
G5817a1	WI-18591	HT0288	1825	tumor necrosis factor alpha-	TCCAGCACTTCTGCA[C/T]CCAGCAACGGCTCCCC	M	C	T	T	I
				inducible primary response
				gene B94, ?
G5817a2	WI-18592	HT0288	1835	tumor necrosis factor alpha-	CTGCACCCAGCACGG[C/T]TCCCCGGCGACCTGG	S	C	T	G	G
				inducible primary response
				gene B94, ?
G5817a3	WI-18747	HT0288	2151	tumor necrosis factor alpha-	GCCTTGGGCACACCC[C/T]GCTGGGAGCTGTTAA	—	C	T
				inducible primary response
				gene B94, ?
G5836a2	WI-18777	HT1549	892	CSK, c-src tyrosine kinase	GGTGCAGCTCCTGGG[C/T]GTGATCGTGGAGGAG	S	C	T	G	G
G5836a3	WI-18778	HT1549	925	CSK, c-src tyrosine kinase	GGGCGGGCTCTACAT[C/T]GTCACTGAGTACATG	S	C	T	I	I
G5836a4	WI-18779	HT1549	974	CSK, c-src tyrosine kinase	GACTACCTGCGGTCT[A/C]GGGGTCGGTCAGTGC	S	A	C	R	R
G5869a1	WI-18954	HT0929	3985	ITK, IL2-inducible T-cell	ACCAGCCCAGGACCC[T/C]CCAGAGGCAGCCTGG	—	T	C
				kinase
G5869a2	WI-18955	HT0929	4036	ITK, IL2-inducible T-cell	CACCATGGAAGCAGC[A/C]TCCTGACCACAGCTG	—	A	C
				kinase
G5870a1	WI-18956	HT3217	1038	PTPN2, protein tyrosine	AGAAGAAAAACTGAC[A/C]GGTGACCGATGTACA	S	A	C	T	T
				phosphatase, non-receptor
				type 2
G5908a1	WI-18549	HT1444	798	UCHL1, ubiquitin carboxyl-	TTCTGCAGACACGCC[T/C]TCCCCTCAGCCACAC	—	T	C
				terminal esterase L1
				(ubiquitin thiolesterase)
G5909a1	WI-18878	HT0284	494	ubiqiutin carrier protein E2-	CTACGAGGAGTATGC[G/A]GCTCGGGCCCGTCTG	S	G	A	A	A
				EPF, ?
G5909a2	WI-18879	HT0284	507	ubiquitin carrier protein E2-	GCGGCTCGGGCCCGT[C/T]TGCTCACAGAGATCC	S	C	T	L	L
				EPF, ?
G5909a3	WI-18880	HT0284	586	ubiquitin carrier protein E2-	TGGCCAGTGGCACTG[A/C]AGCTTCCTCCACCGA	M	A	C	E	A
				EPF, ?
G5909a4	WI-18881	HT0284	615	ubiquitin carrier protein E2-	GACCCTGGGGCCCCA[G/T]GGGGCCCGGGAGGGG	M	G	T	G	W
				EPF, ?
G5909a5	WI-18882	HT0284	622	ubiquitin carrier protein E2-	GGGCCCCAGGGGGCC[C/T]GGGAGGGGCTGAGGG	M	C	T	P	L
				EPF, ?
G5909a6	WI-18883	HT0284	623	ubiquitin carrier protein E2-	GGCCCCAGGGGGCCC[G/A]GGAGGGGCTGAGGGT	S	G	A	P	P
				EPF, ?
G5909a7	WI-18884	HT0284	563	ubiquitin carrier protein E2-	CAGGGCCGAAGCCGG[T/G]CGGGCCCTGGCCAGT	S	T	G	G	G
				EPF, ?
G5922a1	WI-18929	HT0037	513	Unknown protein product	AGGTGGTGACCTGCA[G/A]AAAGCAGGAAAGCTC	S	G	A	Q	Q
				CIT987SK-A-2A8_1, ?
G5922a2	WI-18930	HT0037	1798	Unknown protein product	GCTATGGATGTTCAA[C/T]TTGTGTGGGAAATAC	M	C	T	L	F
				CIT987SK-A-2A8_1, ?
G5922a3	WI-18931	HT0037	2568	Unknown protein product	GAAAGCTGTTTTGGC[T/C]GAAAGTTATGAAAAA	S	T	C	A	A
				CIT987SK-A-2A8_1, ?
G607a1	WI-19562	HT33636	665	MAPKAPK3, mitogen-activated	GATTTTGGCTTTGCT[A/G]AGGAGACCACCCAAA	M	A	G	K	E
				protein kinase-activated
				protein kinase 3
G6091a1	WI-18583	HT97327	377	cell, ?	AGAAGCATGTTTATT[G/A]CTTCAGAATAAGCAC	M	G	A	C	Y
G6091a2	WI-18584	HT97327	580	cell, ?	GCTGATGAGGATGAC[C/T]GGGAAATTTATGATA	M	C	T	R	W
G6110a1	WI-18567	HT1126	835	CD81, CD81 antigen (target	CGATGACCTCTTCTC[C/T]GGGAAGCTGTACCTC	S	C	T	S	S
				of antiproliferative
				antibody 1)
G6110a2	WI-18568	HT1126	877	CD81, CD81 antigen (target	TGCCATCGTGGTCGC[T/C]GTGATCATGATCTTC	S	T	C	A	A
				of antiproliferative
				antibody 1)
G6112a1	WI-18570	HT5011	397	RANGAP1, Ran GTPase	GGTGTGCAAGGCTTC[G/C]AGGCCCTGCTCAAGA	M	G	C	E	Q
				activating protein 1
G6112a2	WI-18571	HT5011	696	RANGAP1, Ran GTPase	CCTGGCCCAGGCTTT[C/T]GCTGTCAACCCCCTG	S	C	T	F	F
				activating protein 1
G6112a3	WI-18572	HT5011	870	RANGAP1, Ran GTPase	AGATGCCATCCGCGG[C/T]GGCCTGCCCAAGCTA	S	C	T	G	G
				activating protein 1
G5112a4	WI-18573	HT5011	1201	RANGAP1, Ran GTPase	GAAGAGCCTCAGCAG[C/G]GAGGGCAGGGAGAGA	M	C	G	R	G
				activating protein 1
G6112a5	WI-18574	HT5011	1548	RANGAP1, Ran GTPase	CTTCCTCACCAGGCT[C/G]CTCGTGCACATGGGT	S	C	G	L	L
				activating protein 1
G619a1	WI-19151	HT2549	1281	calcineurin A1, ?	AAAGTGACAGAAATG[T/C]TGGTAAATGTTCTGA	S	T	C	L	L
G6373a1	WI-18564	HT28143	219	H3FA, H3 histone family,	CCAGCGCCTAGTGCG[C/T]GAGATTGCGCAGGAC	S	C	T	R	R
				member A
G6381a1	WI-18885	HT28122	207	H4FG, H4 histone family,	GAACGTTATTCGAGA[C/T]GCCGTCACCTATACG	S	C	T	D	D
				member G
G6381a2	WI-18886	HT28122	105	H4FG, H4 histone family,	TACAAAACCGGCTAT[C/T]CGCCGTTTGGCTCGG	S	C	T	I	I
				member G
G651a1	WI-18236	HT5206	234	?, ?	CCTCATTGCCTCCTT[T/C]TCACACCGATCCATT	S	T	C	F	F
G6766a1	WI-18887	HT2641	918	major centromere autoantigen	CTCGGGCCTGCGGCA[T/C]GTGCAGCTGGCCTTC	S	T	C	H	H
				CENP-B, ?
G6766a2	WI-18888	HT2641	1208	major centromere autoantigen	GTGAGGGAGAGGAAG[A/G]GGAGGAGGAGGAGGA	M	A	G	E	G
				CENP-B, ?
G683a4	WI-18399	Y08723	419	BMP1, bone morphogenetic	GGGTCATCCCCTTTG[T/C]CATTGGGGGAAACTT	M	T	C	V	A
				protein 1
G683a5	WI-18400	Y08723	544	BMP1, bone morphogenetic	TATATTGTGTTCACC[T/C]ATCGACCTTGAGGGT	M	T	C	Y	H
				protein 1
G6839a1	WI-18889	HT97463	789	non-histone, ?	TGTCTGCTAAACCAG[C/T]TCCTCCAAAACCAGA	M	C	T	A	V
G6839a2	WI-18890	HT97463	889	non-histone, ?	TGCTGGAAAGGATGG[A/G]AACAACCCTGCAAAA	S	A	G	G	G
G6839a3	WI-18891	HT97463	953	non-histone, ?	GCGGAAGGCACTGGG[G/A]ATGCCAAGTGAAATG	M	G	A	D	N
G7000a1	WI-18738	HT0116	1316	MYCL2, v-myc avian	AGTAGATTGCAGAAT[C/G]GATTGCAGCCAGTGC	—	C	G
				myelocytomatosis viral
				oncogene homolog 2
G7000a2	WI-18739	HT0116	1317	MYCL2, v-myc avian	GTAGATTGCAGAATC[G/C]ATTGCAGCCAGTGCA	—	G	C
				myelocytomatosis viral
				oncogene homolog 2
G7086a1	WI-18558	HT27382	1748	DDX8, DEAD/H (Asp-Glu-Ala-	ACCCAGATGTCAATC[C/T]TTGAGCAGAGGGAGA	M	C	T	L	F
				Asp/His) box polypeptide 8
				(RNA helicase)
G7086a2	WI-18559	HT27382	3340	DDX8, DEAD/H (Asp-Glu-Ala-	CATAATGGACAGACA[C/T]AAGCTGGATGTTGTT	S	C	T	H	H
				Asp/His) box polypeptide 8
				(RNA helicase)
G7087a1	WI-18560	HT1506	502	DDX5, DEAD/H (Asp-Glu-Ala-	TGTCATGGATGTTAT[T/A]GCAAGACAGAATTTC	S	T	A	I	I
				Asp/His) box polypeptide 5
				(RNA helicase, 68kD)
G7087a2	WI-18561	HT1506	1613	DDX5, DEAD/H (Asp-Glu-Ala-	GTCGAAGACAGAGGT[T/G]CAGGTCGTTCCAGGG	M	T	G	S	A
				Asp/His) box polypeptide 5
				(RNA helicase, 68kD)
G7088a1	WI-18562	HT33614	424	RNA polymerase II, ?	TGAGTAGGGGCCAGA[G/A]GGGGCTCTGCTCGGC	—	G	A
G7088a2	WI-18563	HT33614	436	RNA polymerase II, ?	AGAGGGGGCTCTGCT[C/T]GGCCTGTGAGCCCCG	—	C	T
G7183a1	WI-18553	HT27991	2107	?, ?	CCCAATGCCCCCTGT[G/T]CATCCCCCACCTCCC	S	G	T	V	V
G719a1	WI-18394	X16468	4006	COL2A1, collagen, type II,	CTGGACGAAGCAGCT[G/A]GCAACCTCAAGAAGG	M	G	A	G	S
				alpha 1 (primary
				osteoarthritis,
				spondyloepiphyseal
				dysplasia, congenital)
G7192a1	WI-18875	HT4462	1454	SFRS8, splicing factor,	CAAGTGCACTTGCCC[C/T]CGTGGCCGCCATCAT	M	C	T	P	L
				arginine/serine-rich 8
				(suppressor-of-white-
				apricot, Drosophila homolog)
G7192a2	WI-18876	HT4462	1473	SFRS8, splicing factor,	GGCCGCCATCATCCC[C/T]CCGCCCCCCGACGTC	S	C	T	P	P
				arginine/serine-rich 8
				(suppressor-of-white-
				apricot, Drosophila homolog)
G7192a3	WI-18877	HT4462	2831	SFRS8, splicing factor,	GCTCCAGCCAGGAGC[G/A]CTCCAGGGGAGTCTC	M	G	A	R	H
				arginine/serine-rich 8
				(suppressor-of -white-
				apricot, Drosophila homolog)
G722a8	WI-18274	HT3162	1500	COL4A2, collagen, type IV,	GGGCTCCTGCCTGGC[G/A]CGGTTCAGCACCATG	S	G	A	A	A
				alpha 2
G722a9	WI-18275	HT3162	1756	COL4A2, collagen, type IV,	TGGATCGGATATTCC[T/C]TCCTCATGCACACGG	M	T	C	F	L
				alpha 2
G722a10	WI-18276	HT3162	1173	COL4A2, collagen, type IV,	CGGAGAACCAGGTTT[T/C]CGTGGGGCTCCAGGG	S	T	C	F	F
				alpha 2
G722a11	WI-18277	HT3162	1283	COL4A2, collagen, type IV,	GGCCGATTGGCCAAG[A/C]AGGTGCACCAGGCCG	M	A	C	E	A
				alpha 2
G722a12	WI-18278	HT3162	1398	COL4A2, collagen, type IV,	GGAGCCCATGTGCCC[G/A]GTGGGCATGAACAAA	S	G	A	P	P
				alpha 2
G7224a1	WI-18914	HT2862	261	PLS3, plastin 3 (T isoform)	GAGAGAAATTATTCA[G/T]AAACTCATGCTGGAT	M	G	T	Q	H
G7224a2	WI-18915	HT2862	1329	PLS3, plastin 3 (T isoform)	TCTTGGTGTCAATCC[T/C]CACGTAAACCATCTC	S	T	C	P	P
G7224a3	WI-18916	HT2862	1381	PLS3, plastin 3 (T isoform)	CTGGTAATCTTACAG[T/C]TATATGAACGAATTA	S	T	C	L	L
G7224a4	WI-18917	HT2862	1522	PLS3, plastin 3 (T isoform)	GCTAAATTCTCCCTG[G/A]TTGGCATTGGAGGGC	M	G	A	V	I
G7224a5	WI-18918	HT2862	1537	PLS3, plastin 3 (T isoform)	GTTGGCATTGGAGGG[C/G]AAGACCTGAATGATG	M	C	G	Q	E
G759a1	WI-18398	U08032	250	SULT1A1, sulfotransferase	GTACGGGTGCCCTTC[C/T]TTGAGGTCAATGATC	M	C	T	L	F
				family 1A, phenol-
				preferring, member 1
G804a16	WI-18818	Z26653	130	LAMA2, laminin, alpha 2	GCAGCGGCCGCAGCA[G/C]CAGCGGCAGTCACAG	M	G	C	Q	H
				(merosin, congenital
				muscular dystrophy)
G804a17	WI-18819	Z26653	205	LAMA2, laminin, alpha 2	TTCTAATGCTCTTAT[C/T]ACGACCAATGCAACA	S	C	T	I	I
				(merosin, congenital
				muscular dystrophy)
G804a18	WI-18820	Z26653	2143	LAMA2, laminin, alpha 2	GATGGATGCCATCTT[C/T]AGGTTGAGCTCTGTT	S	C	T	F	F
				(merosin, congenital
				muscular dystrophy)
G804a19	WI-18823	Z26653	3662	LAMA2, laminin, alpha 2	GAGGCTCTGCAGCAC[A/G]CGACCACCAAGGGCA	M	A	G	T	A
				(merosin, congenital
				muscular dystrophy)
G804a20	WI-18829	Z26653	7809	LAMA2, laminin, alpha 2	GACAGGCCTATTATG[T/C]AATACTCCTCAACAG	M	T	C	V	A
				(merosin, congenital
				muscular dystrophy)
G804a21	WI-18830	Z26653	7879	LAMA2, laminin, alpha 2	AATGAGGAAAATTGT[C/G]ATCAGACCAGAGCCG	S	C	G	V	V
				(merosin, congenital
				muscular dystrophy)
G804a22	WI-18831	Z26653	7894	LAMA2, laminin, alpha 2	CATCAGACCAGAGCC[G/AAATCTGTTTCATGAT	S	G	A	P	P
				(merosin, congenital
				muscular dystrophy)
G804a23	WI-18832	Z26653	7955	LAMA2, laminin, alpha 2	ACTAGAGGCATCTTT[A/G]CAGTTCAAGTGGATG	M	A	G	T	A
				(merosin, congenital
				muscular dystrophy)
G804a24	WI-18873	Z26653	5883	LAMA2, laminin, alpha 2	AAGTTGCCAAAGAAG[C/T]CAAAGATCTTGCACA	M	C	T	A	V
				(merosin, congenital
				muscular dystrophy)
G8089a1	WI-18387	U39550	1004	Homo sapiens UDP-	ATATGATCTCTACAG[T/C]CACACATCAATTTGG	S	T	C	S	S
				glucuronosyltransferase
				(UGT1J) gene, exon 1,
				partial cds., ?
G8089a2	WI-18388	U39550	977	Homo sapiens UDP-	TGAAATTCTCCAAAC[C/A]CCTGTCACGGCATAT	S	C	A	T	T
				glucuronosyltransferase
				(UGT1J) gene, exon 1,
				partial cds., ?
G8089a3	WI-18389	U39550	983	Homo sapiens UDP-	TCTCCAAACCCCTGT[C/T]ACGGCATATGATCTC	S	C	T	V	V
				glucuronosyltransferase
				(UGT1J) gene, exon 1,
				partial cds., ?
G8157a1	WI-18227	AF084644	1160	NR1I2, nuclear receptor	GCTGAAATTCCACTA[C/T]ATGCTGAAGAAGCTG	S	C	T	Y	Y
				subfamily 1, group I, member
				2
G83a8	WI-18180	HT1576	4317	DNMT1, DNA (cytosine-5-)-	CTGGCGCGATCTGCC[C/T]AACATCGAGGTGCGG	S	C	T	P	P
				methyltransferase 1
G840a4	WI-18411	L13858	2159	SOS1, son of sevenless	TCATTTCAAGTGTAA[G/A]AGGGAAAGCTATGAA	M	G	A	R	K
				(Drosophila) homolog 1
G8675a1	WI-18245	NM_002039	1251	?, ?	GTTACTGTATCCCTA[C/T]AGCAGGGATGTCGCC	M	C	T	T	I
G8675a2	WI-18620	NM_002039	2011	?, ?	GGAATACTTAGATCT[C/T]GACTTAGATTCTGGG	S	C	T	L	L
G8697a1	WI-18244	U65065	3006	?, ?	CTCGAGGGGAGCCCC[C/T]ACCCCACGGATGTTG	—	C	T
G898a5	WI-18279	X96783	1051	SYT5, synaptotagmin 5	CTTCGCCTTCAAGGT[C/A]CCCTACGTGGAGCTG	S	C	A	V	V
G898a6	WI-18280	X96783	1078	SYT5, synaptotagmin 5	GCTGGGGGGCAGGGT[G/A]CTGGTCATGGCGGTG	S	G	A	V	V
G898a7	WI-18281	X96783	1142	SYT5, synaptotagmin 5	ATCGGGGAGGTGCGG[G/A]TCCCTATGAGCTCCG	M	G	A	V	I
G898a8	WI-18282	X96783	1271	SYT5, synaptotagmin 5	GTCCCCACGGCCGGG[A/G]AGCTCACCGTCATCG	M	A	G	K	E
G909a1	WI-18237	HT3173	189	DNM1, dynamin 1	GGTGGGCGGCCAGAG[C/T]GCCGGCAAGAGCTCG	S	C	T	S	S
G909a2	WI-18238	HT3173	378	DNM1, dynamin 1	TGAGATCGAGGCCGA[G/A]ACCGACAGGGTCACC	S	G	A	E	E
G909a3	WI-18239	HT3173	423	DNM1, dynamin 1	CATCTCGCCGGTGCC[T/C]ATCAACCTCCGCGTC	S	T	C	P	P
G957a23	WI-19441	HT3419	190	calcium channel, voltage,	CGGCAGAACTGTTTC[A/G]CCGTCAACAGATCCC	—	A	G
				gated, alpha 1E subunit,
				alt. transcript 2, ?
G957a24	WI-19442	HT3419	2574	calcium channel, voltage-	GTCCCTCAAGGGGGA[T/A]GGAGGGGACCGATCC	M	T	A	D	E
				gated, alpha 1E subunit,
				alt. transcript 2, ?
G957a25	WI-19443	HT3419	3444	calcium channel, voltage-	GGCCTGCCACTACAT[C/T]GTGAACCTGCGCTAC	S	C	T	I	I
				gated, alpha 1E subunit,
				alt. transcript 2, ?
G957a26	WI-19444	HT3419	3455	calcium channel, voltage-	ACATCGTGAACCTGC[G/C]CTACTTTGAGATGTG	M	G	C	R	P
				gated, alpha 1E subunit,
				alt. transcript 2, ?
G957a27	WI-19543	HT3419	1308	calcium channel, voltage-	CTGTGTTGATATCTC[C/G]TCTGTGGGCACACCT	—	C	G
				gated, alpha 1E subunit,
				alt. transcript 2, ?
G957a28	WI-19544	HT3419	2809	calcium channel, voltage-	TCCTCTTCAGCCTCC[C/T]GGAGCAGGTCTGCCA	M	C	T	R	W
				gated, alpha 1E subunit,
				alt. transcript 2, ?
G957a29	WI-19545	HT3419	2984	calcium channel, voltage-	GAGGCTCCGGGCTGG[C/T]AGGAGGCCTTGATGA	M	C	T	A	V
				gated, alpha 1E subunit,
				alt. transcript 2, ?
G957a30	WI-19546	HT3419	2989	calcium channel, voltage-	TCCGGGCTGGCAGGA[G/T]GCCTTGATGAGGCTG	M	G	T	G	C
				gated, alpha 1E subunit,
				alt. transcript 2, ?
G957a31	WI-19547	HT3419	3000	calcium channel, voltage-	AGGAGGCCTTGATGA[G/T]GCTGACACCCCCCTA	M	G	T	E	D
				gated, alpha 1E subunit,
				alt. transcript 2, ?
G957a32	WI-19548	HT3419	3033	calcium channel, voltage-	CCTGCCCCATCCTGA[G/T]CTGGAAGTGGGGAAG	M	G	T	E	D
				gated, alpha 1E subunit,
				alt. transcript 2, ?
G957a33	WI-19549	HT3419	4005	calcium channel, voltage-	CAACTATGTAGATCA[T/C]GAGAAAAACAAGATG	—	T	C
				gated, alpha 1E subunit,
				alt. transcript 2, ?
G957a34	WI-19550	HT3419	5070	calcium channel, voltage-	AGGGCAGAACGAGAA[C/T]GAACGCTGCGGCACC	—	C	T
				gated, alpha 1E subunit,
				alt. transcript 2, ?
G957a35	WI-19551	HT3419	5808	calcium channel, voltage-	GAGTGGATACCCTTC[G/A]ATGAGTCCACTCTCT	S	G	A	S	S
				gated, alpha 1E subunit,
				alt. transcript 2, ?
G957a36	WI-19552	HT3419	5841	calcium channel, voltage-	CCAGGATATATTCCA[G/A]TTGGCTTGTATGGAC	S	G	A	Q	Q
				gated, alpha 1E subunit,
				alt. transcript 2, ?
G957a37	WI-19553	HT3419	5860	calcium channel, voltage-	GCTTGTATGGACCCC[A/G]CCGATGACGGACAGT	—	A	G
				gated, alpha 1E subunit,
				alt, transcript 2, ?
G957a38	WI-19554	HT3419	5922	calcium channel, voltage-	TAGTGAATTAAAAAG[C/T]GTGCAGCCCTCTAAC	—	C	T
				gated, alpha 1E subunit,
				alt. transcript 2, ?
G957a39	WI-19555	HT3419	6564	calcium channel, voltage-	ACCTGCTGATGGAAG[C/T]GAGGAGGGCTCCCCG	—	C	T
				gated, alpha 1E subunit,
				alt. transcript 2, ?
TBXAS1a33	WI-19565	M80647	912	TBXAS1, thromboxane A	GATTTTGCCCAATAA[G/A]AACCGAGACGAACTG	S	G	A	K	K
				synthase 1 (platelet,
				cytochrome P450, subfamily
				V)
TEXAS1a34	WI-19566	M80647	1111	TBXAS1, thromboxane A	GGGTGCAAGCCGAAC[C/G]CTTCCCGGCAACACC	M	C	G	P	A
				synthase 1 (platelet,
				cytochrome P450, subfamily
				V)

[0114] From the foregoing, it is apparent that the invention includes a number of general uses that can be expressed concisely as follows. The invention provides for the use of any of the nucleic acid segments described above in the diagnosis or monitoring of diseases, such as cancer, inflammation, heart disease, diseases of the cardiovascular system, and infection by microorganisms. The invention further provides for the use of any of the nucleic acid segments in the manufacture of a medicament for the treatment or prophylaxis of such diseases. The invention further provides for the use of any of the DNA segments as a pharmaceutical.

[0115] While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.

Claims

1. A nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of the nucleic acid sequences listed in the Table, wherein said nucleic acid sequence is at least 10 nucleotides in length and comprises a polymorphic site identified in the Table, and wherein the nucleotide at the polymorphic site is different from a nucleotide at the polymorphic site in a corresponding reference allele.

2. A nucleic acid molecule according to claim 1, wherein said nucleic acid sequence is at least 15 nucleotides in length.

3. A nucleic acid molecule according to claim 1, wherein said nucleic acid sequence is at least 20 nucleotides in length.

4. A nucleic acid molecule according to claim 1, wherein the nucleotide at the polymorphic site is the variant nucleotide for the nucleic acid sequence listed in the Table.

5. An allele-specific oligonucleotide that hybridizes to a portion of a nucleic acid sequence selected from the group consisting of the nucleic acid sequences listed in the Table, wherein said portion is at least 10 nucleotides in length and comprises a polymorphic site identified in the Table, and wherein the nucleotide at the polymorphic site is different from a nucleotide at the polymorphic site in a corresponding reference allele.

6. An allele-specific oligonucleotide according to claim 5 that is a probe.

7. An allele-specific oligonucleotide according to claim 5, wherein a central position of the probe aligns with the polymorphic site of the portion.

8. An allele-specific oligonucleotide according to claim 5 that is a primer.

9. An allele-specific oligonucleotide according to claim 8, wherein the 3′ end of the primer aligns with the polymorphic site of the portion.

10. An isolated gene product encoded by a nucleic acid molecule according to claim 1.

11. A method of analyzing a nucleic acid sample, comprising obtaining the nucleic acid sample from an individual; and determining a base occupying any one of the polymorphic sites shown in the Table.

12. A method according to claim 11, wherein the nucleic acid sample is obtained from a plurality of individuals, and a base occupying one of the polymorphic positions is determined in each of the individuals, and wherein the method further comprising testing each individual for the presence of a disease phenotype, and correlating the presence of the disease phenotype with the base.

13. An oligonucleotide microarray having immobilized thereon a plurality of oligonucleotide probes specific for one or more nucleic acid molecules comprising a nucleic acid sequence selected from the group consisting of the nucleic acid sequences listed in the Table.